Chr	Start	End	Ref	Alt	CGI_annotation
chr14	105243048	105243048	G	T	Biomarker=AKT1:Q79K;Evidence_level=Case report;Association=Resistant;Drug=BRAF inhibitors;Tumor_type=Cutaneous melanoma
chr14	105246551	105246551	C	T	Biomarker=AKT1:E17K;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Case report|Early trials;Association=Resistant|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BRAF inhibitors|AKT inhibitors|allosteric AKT inhibitors|non-allosteric AKT inhibitors|PI3K pathway inhibitors|Tensirolimus (MTOR inhibitor);Tumor_type=Cutaneous melanoma|Any cancer type|Any cancer type|Any cancer type|Head an neck squamous|Endometrium
chr9	133748283	133748283	C	T	Biomarker=ABL1:T315I;Evidence_level=Pre-clinical|FDA guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Responsive|Resistant|Resistant|Resistant;Drug=Axitinib (VEGFR inhibitor)|Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|BCR-ABL inhibitor 2nd gens (Nilotinib_Dasatinib_etc)|Bosutinib (BCR-ABL inhibitor  3rd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Any cancer type|Chronic myeloid leukemia;Acute lymphoblastic leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748282	133748282	A	G	Biomarker=ABL1:T315A;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Nilotinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748288	133748288	T	C	Biomarker=ABL1:F317L;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Nilotinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748288	133748288	T	G	Biomarker=ABL1:F317V;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Nilotinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748288	133748288	T	A	Biomarker=ABL1:F317I;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Nilotinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748289	133748289	T	G	Biomarker=ABL1:F317C;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Nilotinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133738357	133738357	T	C	Biomarker=ABL1:Y253H;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133738363	133738363	G	A	Biomarker=ABL1:E255K;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133738364	133738364	A	T	Biomarker=ABL1:E255V;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748414	133748414	T	G	Biomarker=ABL1:F359V;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748415	133748415	T	G	Biomarker=ABL1:F359C;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133748414	133748414	T	A	Biomarker=ABL1:F359I;Evidence_level=NCCN guidelines|NCCN guidelines|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Resistant|Resistant;Drug=Bosutinib (BCR-ABL inhibitor  3rd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia|Chronic myeloid leukemia
chr9	133747588	133747588	G	C	Biomarker=ABL1:V299L;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|Pre-clinical|European LeukemiaNet guidelines|European LeukemiaNet guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Resistant|Resistant;Drug=Cabozantinib (Pan-kinase inhibitor)|Crizotinib (ALK inhibitor)|Foretinib  (MET inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|Vandetanib (Pan-TK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Any cancer type|Any cancer type|Any cancer type|Chronic myeloid leukemia|Any cancer type|Chronic myeloid leukemia|Chronic myeloid leukemia
chr7	140453136	140453136	A	T	Biomarker=BRAF:V600E;Evidence_level=Case report|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|NCCN guidelines|FDA guidelines|Case report|Early trials|Case report|FDA guidelines|FDA guidelines|Early trials|Pre-clinical|Early trials|FDA guidelines|Case report|Early trials|FDA guidelines|Early trials|NCCN guidelines|FDA guidelines|Late trials|Late trials;Association=Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant|Resistant;Drug=EGFR TK inhibitors|BRAF inhibitor + CDK2/4 inhibitors|BRAF inhibitor + HSP90 inhibitors|BRAF inhibitor + MEK inhibitors|BRAF inhibitor + PI3K pathway inhibitors|BRAF inhibitors|BRAF inhibitors|ERK inhibitors|ERK inhibitors|MEK inhibitors|MEK inhibitors|Pan-RAF inhibitors|Dabrafenib (BRAF inhibitor)|Dabrafenib (BRAF inhibitor)|Dabrafenib (BRAF inhibitor)|Dabrafenib (BRAF inhibitor)|Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)|Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)|Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)|Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)|Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)|PLX4720 (BRAF inhibitor)|Selumetinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)|Cetuximab (EGFR mAb inhibitor)|Panitumumab (EGFR mAb inhibitor);Tumor_type=Lung adenocarcinoma|Cutaneous melanoma|Cutaneous melanoma|Thyroid|Cutaneous melanoma|Glioma|Ovary|Cutaneous melanoma|Lung adenocarcinoma|Thyroid|Ovary|Cutaneous melanoma|Lung adenocarcinoma;Thyroid|Non-small cell lung|Cutaneous melanoma|Gastrointestinal stromal|Colorectal adenocarcinoma|Neuroendocrine|Lung adenocarcinoma|Cutaneous melanoma|Colorectal adenocarcinoma|Malignant astrocytoma|Pediatric glioma|Cutaneous melanoma|Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma|Malignant astrocytoma|Cutaneous melanoma|Thyroid carcinoma|Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis|Cutaneous melanoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma
chr7	140481402	140481402	C	G	Biomarker=BRAF:G469A;Evidence_level=Case report|Case report;Association=Resistant|Responsive;Drug=EGFR TK inhibitors|ERK inhibitors;Tumor_type=Lung adenocarcinoma|Head an neck squamous
chr14	105239908	105239908	G	A	Biomarker=AKT1:H238Y;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Fibrous histiocytoma
chr2	29443697	29443697	A	G	Biomarker=ALK:F1174L|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials|Pre-clinical|Case report;Association=Responsive|Resistant|Resistant|Resistant;Drug=novel ALK inhibitors|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung|Glioma|Lung adenocarcinoma
chr2	29416730	29416730	T	A	Biomarker=ALK:E1408V|ALK oncogenic mutation;Evidence_level=Case report|Clinical trials;Association=Responsive|Resistant;Drug=Brigatinib (Pan-TK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung
chr2	29443631	29443631	G	T	Biomarker=ALK:L1196M|ALK oncogenic mutation;Evidence_level=Case report|FDA guidelines|Clinical trials|Case report|Case report;Association=Responsive|Responsive|Resistant|Resistant|Resistant;Drug=Brigatinib (Pan-TK inhibitor)|Ceritinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Lung adenocarcinoma|Non-small cell lung|Non-small cell lung|Lung adenocarcinoma
chr2	29443600	29443600	G	T	Biomarker=ALK:S1206Y|ALK oncogenic mutation;Evidence_level=FDA guidelines|Clinical trials|Case report;Association=Responsive|Resistant|Resistant;Drug=Ceritinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung|Lung adenocarcinoma
chr2	29432682	29432682	C	G	Biomarker=ALK:G1269A|ALK oncogenic mutation;Evidence_level=FDA guidelines|Clinical trials|Case report;Association=Responsive|Resistant|Resistant;Drug=Ceritinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung|Lung adenocarcinoma
chr2	29445213	29445213	A	G	Biomarker=ALK:I1171T|ALK oncogenic mutation;Evidence_level=FDA guidelines|Case report|Clinical trials|Case report;Association=Responsive|Resistant|Resistant|Resistant;Drug=Ceritinib (ALK inhibitor)|Alectinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Lung adenocarcinoma|Non-small cell lung|Lung adenocarcinoma
chr7	55242511	55242511	G	T	Biomarker=EGFR:D761Y;Evidence_level=Case report;Association=Resistant;Drug=EGFR inhibitor 1st gens;Tumor_type=Non-small cell lung
chr7	55249071	55249071	C	T	Biomarker=EGFR:T790M;Evidence_level=Late trials|Late trials|Early trials|Early trials|Pre-clinical|Late trials|Early trials|Early trials|FDA guidelines|NCCN/CAP guidelines|NCCN/CAP guidelines;Association=Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant|Resistant;Drug=EGFR inhibitor 1st gens|EGFR inhibitor 2nd gens|EGFR inhibitor 3rd gens|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|EGFR inhibitor 3rd gens (Rociletinib_HM61713_etc)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Osimertinib (EGFR inhibitor 3rd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Non-small cell lung|Non-small cell lung|Lung|Lung|Lung|Non-small cell lung|Lung|Lung|Non-small cell lung|Lung|Lung
chr2	29455235	29455235	A	G	Biomarker=ALK:F856S|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Acute myeloid leukemia|Non-small cell lung
chr2	29754892	29754892	G	T	Biomarker=ALK:A348D|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Acute myeloid leukemia|Non-small cell lung
chr2	29443625	29443625	G	A	Biomarker=ALK:L1198F|ALK oncogenic mutation;Evidence_level=Case report|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung
chr2	29432664	29432664	C	T	Biomarker=ALK:R1275Q|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Glioma|Non-small cell lung
chr2	29445450	29445450	C	G	Biomarker=ALK:G1128A|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Glioma|Non-small cell lung
chr2	29445213	29445213	A	T	Biomarker=ALK:I1171N|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Glioma|Non-small cell lung
chr2	29443642	29443642	C	G	Biomarker=ALK:R1192P|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Glioma|Non-small cell lung
chr2	29436859	29436859	A	C	Biomarker=ALK:F1245C|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials;Association=Responsive|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Glioma|Non-small cell lung
chr2	29445258	29445258	C	T	Biomarker=ALK:C1156Y|ALK oncogenic mutation;Evidence_level=Pre-clinical|Clinical trials|Case report|Case report;Association=Responsive|Resistant|Resistant|Resistant;Drug=Lorlatinib (ALK&ROS1 inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung|Non-small cell lung|Lung adenocarcinoma
chrX	47426121	47426121	C	G	Biomarker=ARAF:S214C|ARAF oncogenic mutation;Evidence_level=Case report|Case report|Case report;Association=Resistant|Resistant|Responsive;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors|Sorafenib (Pan-TK inhibitor);Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung adenocarcinoma
chr4	1807494	1807494	G	A	Biomarker=FGFR3:V555M|FGFR3 oncogenic mutation;Evidence_level=Pre-clinical|Early trials;Association=Resistant|Responsive;Drug=FGFR inhibitors|FGFR inhibitors;Tumor_type=Myeloma|Bladder
chr7	140453145	140453145	A	C	Biomarker=BRAF:L597R;Evidence_level=Case report|Case report;Association=Responsive|Responsive;Drug=BRAF inhibitors|MEK inhibitors (Trametinib_etc);Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr7	140477854	140477854	A	C	Biomarker=BRAF:L485W;Evidence_level=Case report;Association=Responsive;Drug=ERK inhibitors;Tumor_type=Billiary tract
chr7	140453133	140453133	T	C	Biomarker=BRAF:K601R;Evidence_level=Case report;Association=Responsive;Drug=MEK inhibitors (Trametinib_etc);Tumor_type=Cutaneous melanoma
chr7	140453136	140453137	AC	CT	Biomarker=BRAF:V600R;Evidence_level=Case report|Early trials|NCCN guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitors (Trametinib_etc)|Dabrafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
chr12	25398281	25398281	C	T	Biomarker=KRAS:G13D|KRAS oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Cetuximab (EGFR mAb inhibitor)|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Colorectal adenocarcinoma|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr7	140453136	140453137	AC	TT	Biomarker=BRAF:V600K;Evidence_level=FDA guidelines|FDA guidelines|NCCN guidelines|NCCN guidelines|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)|Trametinib (MEK inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor)|Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis|Cutaneous melanoma
chr7	140481411	140481411	C	A	Biomarker=BRAF:G466V;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung adenocarcinoma
chr7	140481393	140481393	T	C	Biomarker=BRAF:Y472C;Evidence_level=Case report;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung adenocarcinoma
chr7	140453154	140453154	T	C	Biomarker=BRAF:D594G;Evidence_level=Pre-clinical;Association=Responsive;Drug=Sorafenib (Pan-TK inhibitor);Tumor_type=Cutaneous melanoma
chr7	140481402	140481402	C	T	Biomarker=BRAF:G469E;Evidence_level=Pre-clinical;Association=Responsive;Drug=Sorafenib (Pan-TK inhibitor);Tumor_type=Cutaneous melanoma
chr7	140453135	140453136	CA	GT	Biomarker=BRAF:V600D;Evidence_level=NCCN guidelines|NCCN guidelines;Association=Responsive|Responsive;Drug=Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
chr7	140453137	140453137	C	T	Biomarker=BRAF:V600M;Evidence_level=NCCN guidelines|NCCN guidelines;Association=Responsive|Responsive;Drug=Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
chr7	140453136	140453136	A	C	Biomarker=BRAF:V600G;Evidence_level=NCCN guidelines|NCCN guidelines;Association=Responsive|Responsive;Drug=Vemurafenib (BRAF inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
chr11	119148891	119148891	T	C	Biomarker=CBL:Y371H;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=JAK inhibitors|Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Myelodisplasic proliferative syndrome|Myelodisplasic proliferative syndrome
chr11	119148930	119148930	T	C	Biomarker=CBL:C384R;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=JAK inhibitors|Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Myelodisplasic proliferative syndrome|Myelodisplasic proliferative syndrome
chr15	66729163	66729163	C	T	Biomarker=MAP2K1:P124L|MAP2K1 oncogenic mutation|MAP2K1 (Q56P_P124S_P124L;Evidence_level=Case report|Case report|Case report|Case report;Association=Resistant|Resistant|Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors|MEK inhibitors|BRAF inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma
chr15	66727455	66727455	G	C	Biomarker=MAP2K1:K57N|MAP2K1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr15	66729153	66729153	T	A	Biomarker=MAP2K1:C121S|MAP2K1 oncogenic mutation|MAP2K1 (Q56P_P124S_P124L;Evidence_level=Case report|Case report|Pre-clinical|Case report;Association=Resistant|Resistant|Responsive|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors|novel MEK inhibitors|BRAF inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma
chr15	66727451	66727451	A	C	Biomarker=MAP2K1:Q56P|MAP2K1 oncogenic mutation|MAP2K1 (Q56P_P124S_P124L;Evidence_level=Case report|Case report|Pre-clinical|Case report|Case report;Association=Resistant|Resistant|Responsive|Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors|Trametinib (MEK inhibitor)|Vemurafenib (BRAF inhibitor)|BRAF inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma|Any cancer type|Cutaneous melanoma|Cutaneous melanoma
chr15	66729162	66729162	C	T	Biomarker=MAP2K1:P124S|MAP2K1 oncogenic mutation|MAP2K1 (Q56P_P124S_P124L;Evidence_level=Case report|Case report|Case report;Association=Resistant|Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors|BRAF inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma|Cutaneous melanoma
chr5	149441328	149441328	A	C	Biomarker=CSF1R:Y571D;Evidence_level=Pre-clinical;Association=Responsive;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Myelodisplasic proliferative syndrome
chr19	4117541	4117541	T	G	Biomarker=MAP2K2:Q60P;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitors|MEK inhibitors;Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr3	41266109	41266109	C	T	Biomarker=CTNNB1:H36Y|CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials;Association=Resistant|Responsive;Drug=Tankyrase inhibitors|Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy);Tumor_type=Colorectal adenocarcinoma|Endometrium
chr3	41266113	41266113	C	G	Biomarker=CTNNB1:S37C|CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials;Association=Resistant|Responsive;Drug=Tankyrase inhibitors|Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy);Tumor_type=Colorectal adenocarcinoma|Endometrium
chr3	41266113	41266113	C	A	Biomarker=CTNNB1:S37Y|CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials;Association=Resistant|Responsive;Drug=Tankyrase inhibitors|Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy);Tumor_type=Colorectal adenocarcinoma|Endometrium
chr3	41266098	41266098	A	T	Biomarker=CTNNB1:D32V|CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials;Association=Resistant|Responsive;Drug=Tankyrase inhibitors|Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy);Tumor_type=Colorectal adenocarcinoma|Endometrium
chr19	4117617	4117617	C	T	Biomarker=MAP2K2:V35M;Evidence_level=Pre-clinical|Pre-clinical;Association=Resistant|Resistant;Drug=BRAF inhibitors|MEK inhibitors;Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr19	4117584	4117584	G	A	Biomarker=MAP2K2:L46F;Evidence_level=Pre-clinical|Pre-clinical;Association=Resistant|Resistant;Drug=BRAF inhibitors|MEK inhibitors;Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr19	4110581	4110581	T	C	Biomarker=MAP2K2:N126D;Evidence_level=Pre-clinical|Pre-clinical;Association=Resistant|Resistant;Drug=BRAF inhibitors|MEK inhibitors;Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr19	4110584	4110584	A	T	Biomarker=MAP2K2:C125S;Evidence_level=Pre-clinical|Pre-clinical;Association=Resistant|Resistant;Drug=BRAF inhibitors|MEK inhibitors;Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr1	162745497	162745497	A	T	Biomarker=DDR2:I638F;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell
chr1	162729630	162729630	T	G	Biomarker=DDR2:L239R;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell
chr1	162729671	162729671	G	T	Biomarker=DDR2:G253C;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell
chr1	162748407	162748407	G	T	Biomarker=DDR2:G774V;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell
chr1	162724415	162724415	C	G	Biomarker=DDR2:L63V;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell
chr1	162741822	162741822	G	A	Biomarker=DDR2:G505S;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell
chr1	162748390	162748390	T	G	Biomarker=DDR2:S768R;Evidence_level=Case report|Case report;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Lung squamous cell|Lung squamous cell
chr1	97981343	97981343	A	C	Biomarker=DPYD:I560S;Evidence_level=FDA guidelines|FDA guidelines|CPIC guidelines;Association=Increased Toxicity|Increased Toxicity|Increased Toxicity;Drug=Capecitabine (Fluoropyrimidine)|Flourouracil (Fluoropyrimidine)|Tegafur (Fluoropyrimidine);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr1	97547947	97547947	T	A	Biomarker=DPYD:D949V;Evidence_level=FDA guidelines|FDA guidelines|CPIC guidelines;Association=Increased Toxicity|Increased Toxicity|Increased Toxicity;Drug=Capecitabine (Fluoropyrimidine)|Flourouracil (Fluoropyrimidine)|Tegafur (Fluoropyrimidine);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr7	116423408	116423408	A	T	Biomarker=MET:D1246V;Evidence_level=Case report;Association=Resistant;Drug=MET inhibitors;Tumor_type=Lung adenocarcinoma
chr7	55259515	55259515	T	G	Biomarker=EGFR:L858R|EGFR (L858R_L861_G719_S768I);Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|Early trials|FDA guidelines|FDA guidelines|Early trials|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Erlotinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen)|Osimertinib (EGFR inhibitor 3rd gen)|Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung
chr7	55259524	55259524	T	A	Biomarker=EGFR:L861Q;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55241708	55241708	G	C	Biomarker=EGFR:G719A;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55241707	55241707	G	A	Biomarker=EGFR:G719S;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55241707	55241707	G	T	Biomarker=EGFR:G719C;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55241708	55241708	G	A	Biomarker=EGFR:G719D;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55242470	55242470	T	C	Biomarker=EGFR:L747S;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55249005	55249005	G	T	Biomarker=EGFR:S768I|EGFR (L858R_L861_G719_S768I);Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen)|Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung|Non-small cell lung
chr7	55259524	55259524	T	C	Biomarker=EGFR:L861P;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55259524	55259524	T	G	Biomarker=EGFR:L861R;Evidence_level=Late trials|Early trials|Pre-clinical|FDA guidelines|NCCN guidelines|Early trials|FDA guidelines|NCCN guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR TK inhibitors|HSP90 inhibitors|MEK inhibitor (alone or in combination)s|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)|Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)|Gefitinib (EGFR inhibitor 1st gen)|Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Lung|Lung|Lung|Non-small cell lung|Non-small cell lung|Lung|Non-small cell lung|Non-small cell lung
chr7	55228009	55228009	C	G	Biomarker=EGFR:S492R;Evidence_level=Early trials|Case report|Case report;Association=Responsive|Responsive|Resistant;Drug=novel EGFR mAb inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor);Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma
chr7	55231430	55231430	C	T	Biomarker=EGFR:P546S;Evidence_level=Case report;Association=Responsive;Drug=Cetuximab (EGFR mAb inhibitor);Tumor_type=Head an neck
chr7	55242487	55242487	C	T	Biomarker=EGFR:P753S;Evidence_level=Case report;Association=Responsive;Drug=Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor);Tumor_type=Head an neck
chr7	55221822	55221822	C	T	Biomarker=EGFR:A289V;Evidence_level=Pre-clinical;Association=Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Glioma
chr7	55211080	55211080	G	A	Biomarker=EGFR:R108K;Evidence_level=Pre-clinical;Association=Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Glioma
chr7	55233043	55233043	G	T	Biomarker=EGFR:G598V;Evidence_level=Pre-clinical;Association=Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Glioma
chr7	55221743	55221743	A	C	Biomarker=EGFR:T263P;Evidence_level=Pre-clinical;Association=Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Glioma
chr7	55242500	55242500	A	G	Biomarker=EGFR:K757R;Evidence_level=Case report;Association=Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Lung
chr7	55242467	55242467	A	G	Biomarker=EGFR:E746G;Evidence_level=Case report;Association=Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen);Tumor_type=Lung
chr3	178936091	178936091	G	T	Biomarker=PIK3CA:E545*|PIK3CA oncogenic mutation;Evidence_level=Case report|Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BRAF inhibitors|PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Cutaneous melanoma|Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	138374245	138374245	C	A	Biomarker=PIK3CB:D1067Y|PIK3CB oncogenic mutation;Evidence_level=Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|AKT inhibitors|AKT inhibitors|MTORC1/2 inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Breast adenocarcinoma|Head an neck squamous|Breast adenocarcinoma|Head an neck squamous|Breast adenocarcinoma|Head an neck squamous
chr7	55241620	55241620	G	A	Biomarker=EGFR:E690K;Evidence_level=Case report;Association=Responsive;Drug=Lapatinib (ERBB2 inhibitor);Tumor_type=Endometrium
chr1	16464489	16464489	C	T	Biomarker=EPHA2:G391R;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|MTOR inhibitors|Dasatinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Lung squamous cell|Lung squamous cell|Lung squamous cell|Lung squamous cell
chr17	37879601	37879602	TT	AG	Biomarker=ERBB2:V659E|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)|Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Lung|Non-small cell lung|Breast adenocarcinoma;Lung adenocarcinoma|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37868208	37868208	C	T	Biomarker=ERBB2:S310F|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)|Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Lung|Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type|Any cancer type
chr17	37881064	37881064	C	T	Biomarker=ERBB2:T798I|ERBB2 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Case report;Association=Responsive|Responsive|Responsive|Responsive|Resistant;Drug=Afatinib (ERBB2&EGFR inhibitor 2nd gen)|Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Neratinib (ERBB2 inhibitor);Tumor_type=Breast adenocarcinoma|Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma
chr17	37880261	37880261	G	T	Biomarker=ERBB2:D769Y|ERBB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|Pre-clinical|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type
chr17	37880261	37880261	G	C	Biomarker=ERBB2:D769H|ERBB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|Pre-clinical|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type
chr17	37881616	37881616	C	T	Biomarker=ERBB2:R896C|ERBB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|Pre-clinical|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type
chr17	37881000	37881000	G	C	Biomarker=ERBB2:V777L|ERBB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma
chr17	37881332	37881332	G	A	Biomarker=ERBB2:V842I|ERBB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma
chr17	37868205	37868205	G	C	Biomarker=ERBB2:G309A|ERBB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Lapatinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma
chr17	37880213	37880213	A	G	Biomarker=ERBB2:K753E|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Resistant;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Lapatinib (ERBB2 inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma
chr17	37880220	37880220	T	C	Biomarker=ERBB2:L755S|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma
chr17	37881414	37881414	T	G	Biomarker=ERBB2:L869R|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|Early trials;Association=Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Breast adenocarcinoma|Lung adenocarcinoma
chr17	37868205	37868205	G	A	Biomarker=ERBB2:G309E|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type|Any cancer type
chr17	37868208	37868208	C	A	Biomarker=ERBB2:S310Y|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type|Any cancer type
chr17	37868210	37868210	T	C	Biomarker=ERBB2:C311R|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Breast adenocarcinoma;Any cancer type|Any cancer type
chr17	37868241	37868241	A	G	Biomarker=ERBB2:E321G|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Any cancer type
chr17	37868279	37868279	T	A	Biomarker=ERBB2:C334S|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Any cancer type
chr17	37880997	37880998	GG	CT	Biomarker=ERBB2:G776L|ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma|Lung adenocarcinoma
chr12	56481857	56481857	C	A	Biomarker=ERBB3:P262H;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ERBB3 mAb inhibitors|PI3K pathway inhibitor + MEK inhibitors|Lapatinib (ERBB2 inhibitor)|Pertuzumab (ERBB2 mAb inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Any cancer type|Any cancer type|Any cancer type|Any cancer type|Any cancer type
chr12	56481922	56481922	G	A	Biomarker=ERBB3:G284R;Evidence_level=Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ERBB3 mAb inhibitors|PI3K pathway inhibitor + MEK inhibitors|Afatinib (ERBB2&EGFR inhibitor 2nd gen)|Afatinib (ERBB2&EGFR inhibitor 2nd gen)|Lapatinib (ERBB2 inhibitor)|Pertuzumab (ERBB2 mAb inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Any cancer type|Any cancer type|Bladder|Bladder|Any cancer type|Any cancer type|Any cancer type
chr12	56490980	56490980	A	G	Biomarker=ERBB3:Q809R;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Lapatinib (ERBB2 inhibitor)|Trastuzumab (ERBB2 mAb inhibitor);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr12	56478851	56478851	C	G	Biomarker=ERBB3:R103G;Evidence_level=Case report|Case report;Association=Responsive|Responsive;Drug=Afatinib (ERBB2&EGFR inhibitor 2nd gen)|Afatinib (ERBB2&EGFR inhibitor 2nd gen);Tumor_type=Bladder|Bladder
chr12	56478854	56478854	G	A	Biomarker=ERBB3:V104M;Evidence_level=Case report;Association=Responsive;Drug=Afatinib (ERBB2&EGFR inhibitor 2nd gen);Tumor_type=Bladder
chr2	212578308	212578308	C	T	Biomarker=ERBB4:E317K;Evidence_level=Pre-clinical;Association=Responsive;Drug=Lapatinib (ERBB2 inhibitor);Tumor_type=Cutaneous melanoma
chr2	212566827	212566827	C	T	Biomarker=ERBB4:E452K;Evidence_level=Pre-clinical;Association=Responsive;Drug=Lapatinib (ERBB2 inhibitor);Tumor_type=Cutaneous melanoma
chr2	212537975	212537975	G	A	Biomarker=ERBB4:R544W;Evidence_level=Pre-clinical;Association=Responsive;Drug=Lapatinib (ERBB2 inhibitor);Tumor_type=Cutaneous melanoma
chr2	212570064	212570064	G	A	Biomarker=ERBB4:R393W;Evidence_level=Pre-clinical;Association=Responsive;Drug=Lapatinib (ERBB2 inhibitor);Tumor_type=Cutaneous melanoma
chr2	212295699	212295699	C	T	Biomarker=ERBB4:E872K;Evidence_level=Pre-clinical;Association=Responsive;Drug=Lapatinib (ERBB2 inhibitor);Tumor_type=Cutaneous melanoma
chr1	156846342	156846342	G	A	Biomarker=NTRK1:G595R;Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=Pan-TK inhibitors (Entrectinib_etc)|Larotrectinib (Topomyosine kinase inhibitor);Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr1	156849107	156849107	G	T	Biomarker=NTRK1:G667C;Evidence_level=Case report;Association=Resistant;Drug=Pan-TK inhibitors (Entrectinib_etc);Tumor_type=Colorectal adenocarcinoma
chr2	212426689	212426690	TG	CC	Biomarker=ERBB4:H809G;Evidence_level=Case report;Association=Resistant;Drug=ERBB2 inhibitors (Lapatinib_etc);Tumor_type=Breast adenocarcinoma
chrX	66931463	66931463	T	A	Biomarker=AR:L702H;Evidence_level=Early trials;Association=Resistant;Drug=Abiraterone (AR inhibitor);Tumor_type=Prostate adenocarcinoma
chrX	66943552	66943552	A	G	Biomarker=AR:T878A;Evidence_level=Early trials|Case report;Association=Resistant|Resistant;Drug=Abiraterone (AR inhibitor)|Flutamide (AR inhibitor);Tumor_type=Prostate adenocarcinoma|Prostate adenocarcinoma
chr10	123279677	123279677	G	C	Biomarker=FGFR2:S252W;Evidence_level=Pre-clinical;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Endometrium
chr10	123258034	123258034	A	C	Biomarker=FGFR2:N550K;Evidence_level=Pre-clinical;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Endometrium
chr10	123256219	123256219	C	T	Biomarker=FGFR2:V565I|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=FGFR inhibitors|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123279562	123279562	C	A	Biomarker=FGFR2:W290C;Evidence_level=Pre-clinical;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Lung squamous cell
chr10	123278324	123278324	G	C	Biomarker=FGFR2:S320C;Evidence_level=Pre-clinical;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Lung squamous cell
chr10	123247514	123247514	C	G	Biomarker=FGFR2:K660N;Evidence_level=Pre-clinical;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Lung squamous cell
chr4	1803568	1803568	C	G	Biomarker=FGFR3:S249C|FGFR3 oncogenic mutation;Evidence_level=Early trials|Pre-clinical;Association=Responsive|Responsive;Drug=FGFR inhibitors|FGFR inhibitors;Tumor_type=Bladder|Lung adenocarcinoma
chr4	1808313	1808313	G	A	Biomarker=FGFR3:G691R|FGFR3 oncogenic mutation;Evidence_level=Early trials|Pre-clinical;Association=Responsive|Responsive;Drug=FGFR inhibitors|FGFR inhibitors;Tumor_type=Bladder|Lung adenocarcinoma
chrX	66943549	66943549	T	C	Biomarker=AR:F877L;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=Arn-509 (AR inhibitor)|Enzalutamide (AR inhibitor);Tumor_type=Prostate adenocarcinoma|Prostate adenocarcinoma
chr4	1806099	1806099	A	G	Biomarker=FGFR3:Y373C|FGFR3 oncogenic mutation|FGFR3 (K650_Y373C);Evidence_level=Early trials|Pre-clinical|Pre-clinical;Association=Responsive|Resistant|Responsive;Drug=FGFR inhibitors|Bortezomib (Proteasome inhibitor)|FGFR inhibitors;Tumor_type=Bladder|Myeloma|Myeloma
chr2	29445466	29445466	C	T	Biomarker=ALK:G1123S|ALK oncogenic mutation;Evidence_level=Case report|Clinical trials;Association=Resistant|Resistant;Drug=Ceritinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Lung adenocarcinoma|Non-small cell lung
chrX	153762634	153762634	G	A	Biomarker=G6PD:S218F;Evidence_level=FDA guidelines;Association=Increased Toxicity (Haemolytic Anemia);Drug=Dabrafenib (BRAF inhibitor);Tumor_type=Any cancer type
chr6	117639399	117639399	G	T	Biomarker=ROS1:S1986Y;Evidence_level=Case report|Case report|Case report;Association=Resistant|Resistant|Responsive;Drug=Ceritinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Lorlatinib (ALK&ROS1 inhibitor);Tumor_type=Lung adenocarcinoma|Lung adenocarcinoma|Lung adenocarcinoma
chr6	117639399	117639399	G	A	Biomarker=ROS1:S1986F;Evidence_level=Case report|Case report|Case report;Association=Resistant|Resistant|Responsive;Drug=Ceritinib (ALK inhibitor)|Crizotinib (ALK inhibitor)|Lorlatinib (ALK&ROS1 inhibitor);Tumor_type=Lung adenocarcinoma|Lung adenocarcinoma|Lung adenocarcinoma
chr19	3118942	3118942	A	T	Biomarker=GNA11:Q209L;Evidence_level=Pre-clinical|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|Vorinostat (HDAC inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma
chr19	3118942	3118942	A	C	Biomarker=GNA11:Q209P;Evidence_level=Pre-clinical|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|Vorinostat (HDAC inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma
chr15	90631934	90631935	CG	TT	Biomarker=IDH2:R140K|IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=AG-221 (IDH2 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Hematologic malignancies|Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631838	90631838	C	T	Biomarker=IDH2:R172K|IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=AG-221 (IDH2 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Hematologic malignancies|Cholangiocarcinoma|Acute myeloid leukemia
chr7	55227924	55227924	C	T	Biomarker=EGFR:S464L;Evidence_level=Pre-clinical;Association=Resistant;Drug=Cetuximab (EGFR mAb inhibitor);Tumor_type=Colorectal adenocarcinoma
chr7	55227926	55227926	G	A	Biomarker=EGFR:G465R;Evidence_level=Pre-clinical|Case report|Case report;Association=Resistant|Resistant|Resistant;Drug=Cetuximab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|Panitumumab (EGFR mAb inhibitor);Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma
chr7	55228006	55228006	A	G	Biomarker=EGFR:I491M;Evidence_level=Pre-clinical;Association=Resistant;Drug=Cetuximab (EGFR mAb inhibitor);Tumor_type=Colorectal adenocarcinoma
chr7	55227884	55227884	C	T	Biomarker=EGFR:R451C;Evidence_level=Case report;Association=Resistant;Drug=Cetuximab (EGFR mAb inhibitor);Tumor_type=Colorectal adenocarcinoma
chr7	55227933	55227933	A	C	Biomarker=EGFR:K467T;Evidence_level=Case report;Association=Resistant;Drug=Cetuximab (EGFR mAb inhibitor);Tumor_type=Colorectal adenocarcinoma
chr9	5073770	5073770	G	T	Biomarker=JAK2:V617F|JAK2 oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|FDA guidelines;Association=Resistant|Responsive|Responsive|Responsive;Drug=PD1 inhibitors|JAK inhibitor (alone or in combination)s|Ruxolitinib (JAK inhibitor)|Ruxolitinib (JAK inhibitor);Tumor_type=Cutaneous melanoma|Acute myeloid leukemia|Acute myeloid leukemia|Myelofibrosis
chr19	17948009	17948009	G	A	Biomarker=JAK3:A572V;Evidence_level=Pre-clinical;Association=Responsive;Drug=JAK inhibitors;Tumor_type=Lymphoma
chr19	17948006	17948006	G	A	Biomarker=JAK3:A573V;Evidence_level=Pre-clinical;Association=Responsive;Drug=JAK inhibitors;Tumor_type=Lymphoma
chr19	17945969	17945969	C	T	Biomarker=JAK3:R657Q;Evidence_level=Pre-clinical;Association=Responsive;Drug=JAK inhibitors;Tumor_type=Megakaryoblastic leukemia
chr19	17954634	17954634	A	G	Biomarker=JAK3:I87T;Evidence_level=Pre-clinical;Association=Responsive;Drug=JAK inhibitors;Tumor_type=Megakaryoblastic leukemia
chr19	17949138	17949138	C	A	Biomarker=JAK3:Q501H;Evidence_level=Pre-clinical;Association=Responsive;Drug=JAK inhibitors;Tumor_type=Megakaryoblastic leukemia
chr11	128781671	128781671	T	G	Biomarker=KCNJ5:L168R;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=Amiloride (Na-Ca chanel blocker)|Verapamil (Na-Ca chanel blocker);Tumor_type=Adrenal adenoma|Adrenal adenoma
chr4	55955969	55955969	C	T	Biomarker=KDR:A1065T;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors;Tumor_type=Any cancer type
chr4	55599321	55599321	A	T	Biomarker=KIT:D816V;Evidence_level=Early trials|Case report|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Systemic mastocytosis|Acute myeloid leukemia|Any cancer type
chr4	55599320	55599320	G	T	Biomarker=KIT:D816Y;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Any cancer type
chr4	55599320	55599321	GA	TT	Biomarker=KIT:D816F;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Any cancer type
chr4	55599340	55599340	T	G	Biomarker=KIT:N822K;Evidence_level=Pre-clinical;Association=Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Acute myeloid leukemia
chr4	55599332	55599332	G	T	Biomarker=KIT:D820Y;Evidence_level=Case report|Case report;Association=Responsive|Responsive;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr4	55593591	55593591	T	A	Biomarker=KIT:Y553N;Evidence_level=Case report|Case report;Association=Responsive|Responsive;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Sunitinib (Pan-TK inhibitor);Tumor_type=Thymic|Thymic
chr4	55602664	55602664	G	C	Biomarker=KIT:A829P|KIT (V559I_H697Y_T670_V654A_A829P_D816_N822_Y823D);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Gastrointestinal stromal|Gastrointestinal stromal
chr4	55594258	55594258	T	C	Biomarker=KIT:V654A|KIT (V559I_H697Y_T670_V654A_A829P_D816_N822_Y823D);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Gastrointestinal stromal|Gastrointestinal stromal
chr4	55595519	55595519	C	T	Biomarker=KIT:T670I;Evidence_level=Pre-clinical|Case report;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Gastrointestinal stromal|Gastrointestinal stromal
chr4	55599334	55599334	T	G	Biomarker=KIT:D820E;Evidence_level=Case report;Association=Responsive;Drug=Sorafenib (Pan-TK inhibitor);Tumor_type=Thymic
chr4	55595599	55595599	C	T	Biomarker=KIT:H697Y|KIT (V559I_H697Y_T670_V654A_A829P_D816_N822_Y823D);Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Resistant;Drug=Sunitinib (Pan-TK inhibitor)|Sunitinib (Pan-TK inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Thymic|Thymic|Gastrointestinal stromal
chr2	29445270	29445270	A	C	Biomarker=ALK:L1152R|ALK oncogenic mutation;Evidence_level=Clinical trials|Case report;Association=Resistant|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma
chr2	29443613	29443613	C	T	Biomarker=ALK:G1202R|ALK oncogenic mutation;Evidence_level=Clinical trials|Case report;Association=Resistant|Resistant;Drug=Crizotinib (ALK inhibitor)|Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma
chr6	117638347	117638347	C	T	Biomarker=ROS1:G2032R;Evidence_level=Case report|Pre-clinical;Association=Resistant|Responsive;Drug=Crizotinib (ALK inhibitor)|Cabozantinib (Pan-kinase inhibitor);Tumor_type=Lung adenocarcinoma|Lung adenocarcinoma
chr1	11187096	11187096	A	G	Biomarker=MTOR:F2108L;Evidence_level=Case report|Pre-clinical;Association=Resistant|Responsive;Drug=Everolimus (MTOR inhibitor)|MTOR kinase inhibitors;Tumor_type=Thyroid carcinoma|Any cancer type
chr15	66727454	66727454	A	C	Biomarker=MAP2K1:K57T|MAP2K1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Responsive;Drug=EGFR mAb inhibitors|Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor);Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chr6	152419923	152419923	A	C	Biomarker=ESR1:Y537S|ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials|Pre-clinical;Association=Responsive|Resistant|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy)|Fulvestrant (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma|Breast adenocarcinoma
chr7	55259469	55259469	G	A	Biomarker=EGFR:V843I;Evidence_level=Case report;Association=No Responsive;Drug=Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Head an neck
chr7	116417464	116417464	A	G	Biomarker=MET:H1112R;Evidence_level=Early trials|Pre-clinical;Association=Responsive|Responsive;Drug=MET inhibitors|Crizotinib (ALK inhibitor);Tumor_type=Renal|Any cancer type
chr7	116423474	116423474	T	C	Biomarker=MET:M1268T;Evidence_level=Case report|Pre-clinical;Association=Responsive|Responsive;Drug=MET inhibitors|Crizotinib (ALK inhibitor);Tumor_type=Renal|Any cancer type
chr7	116417464	116417464	A	T	Biomarker=MET:H1112L;Evidence_level=Pre-clinical;Association=Responsive;Drug=MET inhibitors (Crizotinib_etc);Tumor_type=Any cancer type
chr7	116417457	116417457	G	A	Biomarker=MET:V1110I;Evidence_level=Pre-clinical;Association=Responsive;Drug=Crizotinib (ALK inhibitor);Tumor_type=Any cancer type
chr7	116411923	116411923	C	T	Biomarker=MET:R988C;Evidence_level=Pre-clinical;Association=Responsive;Drug=Crizotinib (ALK inhibitor);Tumor_type=Any cancer type
chr7	116411990	116411990	C	T	Biomarker=MET:T1010I;Evidence_level=Pre-clinical;Association=Responsive;Drug=Crizotinib (ALK inhibitor);Tumor_type=Any cancer type
chrX	100611165	100611165	A	T	Biomarker=BTK:C481S;Evidence_level=Early trials;Association=Resistant;Drug=Ibrutinib (BTK inhibitor);Tumor_type=Chronic lymphocytic leukemia
chr16	81946260	81946260	C	T	Biomarker=PLCG2:R665W;Evidence_level=Early trials;Association=Resistant;Drug=Ibrutinib (BTK inhibitor);Tumor_type=Chronic lymphocytic leukemia
chr16	81962183	81962183	A	T	Biomarker=PLCG2:L845F;Evidence_level=Early trials;Association=Resistant;Drug=Ibrutinib (BTK inhibitor);Tumor_type=Chronic lymphocytic leukemia
chr9	133738325	133738325	T	C	Biomarker=ABL1:I242T;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738330	133738330	A	G	Biomarker=ABL1:M244V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738340	133738340	A	G	Biomarker=ABL1:K247R;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738342	133738342	C	G	Biomarker=ABL1:L248V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738349	133738349	G	A	Biomarker=ABL1:G250E;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738348	133738348	G	A	Biomarker=ABL1:G250R;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738355	133738355	A	G	Biomarker=ABL1:Q252R;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738356	133738356	G	T	Biomarker=ABL1:Q252H;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738358	133738358	A	T	Biomarker=ABL1:Y253F;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738309	133738309	A	G	Biomarker=ABL1:M237V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738374	133738374	G	C	Biomarker=ABL1:E258D;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738382	133738382	G	T	Biomarker=ABL1:W261L;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133738417	133738417	T	A	Biomarker=ABL1:L273M;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747516	133747516	G	A	Biomarker=ABL1:E275K;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747516	133747516	G	C	Biomarker=ABL1:E275Q;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747520	133747520	A	G	Biomarker=ABL1:D276G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747522	133747522	A	G	Biomarker=ABL1:T277A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747528	133747528	G	A	Biomarker=ABL1:E279K;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747532	133747532	T	C	Biomarker=ABL1:V280A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747559	133747559	T	C	Biomarker=ABL1:V289A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747558	133747558	G	A	Biomarker=ABL1:V289I;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747568	133747568	A	T	Biomarker=ABL1:E292V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747567	133747567	G	C	Biomarker=ABL1:E292Q;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747570	133747570	A	G	Biomarker=ABL1:I293V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133747585	133747585	C	G	Biomarker=ABL1:L298V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748270	133748270	T	C	Biomarker=ABL1:F311L;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748270	133748270	T	A	Biomarker=ABL1:F311I;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748298	133748298	A	G	Biomarker=ABL1:Y320C;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748310	133748310	T	A	Biomarker=ABL1:L324Q;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748363	133748363	T	C	Biomarker=ABL1:Y342H;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748367	133748367	T	C	Biomarker=ABL1:M343T;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748370	133748370	C	T	Biomarker=ABL1:A344V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748388	133748388	C	T	Biomarker=ABL1:A350V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748391	133748391	T	C	Biomarker=ABL1:M351T;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748404	133748404	G	C	Biomarker=ABL1:E355D;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748403	133748403	A	G	Biomarker=ABL1:E355G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748403	133748403	A	C	Biomarker=ABL1:E355A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133748414	133748414	T	C	Biomarker=ABL1:F359L;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750256	133750256	G	T	Biomarker=ABL1:D363Y;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750259	133750259	C	A	Biomarker=ABL1:L364I;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750263	133750263	C	T	Biomarker=ABL1:A365V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750266	133750266	C	G	Biomarker=ABL1:A366G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750278	133750278	T	C	Biomarker=ABL1:L370P;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750281	133750281	T	C	Biomarker=ABL1:V371A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750286	133750286	G	A	Biomarker=ABL1:E373K;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750304	133750304	G	A	Biomarker=ABL1:V379I;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750307	133750307	G	A	Biomarker=ABL1:A380T;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750313	133750313	T	C	Biomarker=ABL1:F382L;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750319	133750319	C	A	Biomarker=ABL1:L384M;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750328	133750328	T	A	Biomarker=ABL1:L387M;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750330	133750330	G	T	Biomarker=ABL1:L387F;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750328	133750328	T	G	Biomarker=ABL1:L387V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750331	133750331	A	C	Biomarker=ABL1:M388L;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750347	133750347	A	G	Biomarker=ABL1:Y393C;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750356	133750356	A	C	Biomarker=ABL1:H396P;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750356	133750356	A	G	Biomarker=ABL1:H396R;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750355	133750356	CA	GC	Biomarker=ABL1:H396A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750358	133750358	G	C	Biomarker=ABL1:A397P;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750419	133750419	C	T	Biomarker=ABL1:S417F;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750419	133750419	C	A	Biomarker=ABL1:S417Y;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750422	133750422	T	G	Biomarker=ABL1:I418S;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133750421	133750421	A	G	Biomarker=ABL1:I418V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753828	133753828	G	A	Biomarker=ABL1:A433T;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753844	133753844	C	G	Biomarker=ABL1:S438C;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753879	133753879	G	A	Biomarker=ABL1:E450K;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753880	133753880	A	G	Biomarker=ABL1:E450G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753880	133753880	A	C	Biomarker=ABL1:E450A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753880	133753880	A	T	Biomarker=ABL1:E450V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753888	133753888	G	A	Biomarker=ABL1:E453K;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753889	133753889	A	G	Biomarker=ABL1:E453G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753889	133753889	A	C	Biomarker=ABL1:E453A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753889	133753889	A	T	Biomarker=ABL1:E453V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753906	133753906	G	A	Biomarker=ABL1:E459K;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753907	133753907	A	G	Biomarker=ABL1:E459G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753907	133753907	A	C	Biomarker=ABL1:E459A;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753907	133753907	A	T	Biomarker=ABL1:E459V;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133753947	133753947	G	C	Biomarker=ABL1:M472I;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133755470	133755470	C	T	Biomarker=ABL1:P480L;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133755488	133755488	T	C	Biomarker=ABL1:F486S;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr9	133755893	133755893	A	G	Biomarker=ABL1:E507G;Evidence_level=European LeukemiaNet guidelines;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Chronic myeloid leukemia
chr1	43815009	43815010	GG	TT	Biomarker=MPL:W515F;Evidence_level=Pre-clinical;Association=Responsive;Drug=JAK inhibitors;Tumor_type=Myelodisplasic proliferative syndrome
chr1	11187857	11187857	C	T	Biomarker=MTOR:E2014K;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Bladder
chr1	11174420	11174420	C	T	Biomarker=MTOR:E2419K;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Bladder
chr1	11227567	11227567	T	C	Biomarker=MTOR:N1421D;Evidence_level=Case report|Case report;Association=Responsive|Responsive;Drug=Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Bladder|Stomach
chr1	11188177	11188177	T	A	Biomarker=MTOR:I1973F;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Angiosarcoma;Renal
chr1	11193189	11193189	T	C	Biomarker=MTOR:K1771R;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Stomach;Anaplastic oligodendroglioma
chr1	11182179	11182179	G	T	Biomarker=MTOR:Q2223K;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr1	11217299	11217299	A	G	Biomarker=MTOR:L1460P;Evidence_level=Pre-clinical;Association=Responsive;Drug=Sirolimus (MTOR inhibitor);Tumor_type=Any cancer type
chr1	11184573	11184573	G	T	Biomarker=MTOR:S2215Y;Evidence_level=Pre-clinical;Association=Responsive;Drug=Sirolimus (MTOR inhibitor);Tumor_type=Any cancer type
chr1	11169361	11169361	C	G	Biomarker=MTOR:R2505P;Evidence_level=Pre-clinical;Association=Responsive;Drug=Sirolimus (MTOR inhibitor);Tumor_type=Any cancer type
chr4	55152093	55152093	A	T	Biomarker=PDGFRA:D842V;Evidence_level=Late trials_Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Late trials_Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|HSP90 inhibitors|Crenolanib (FLT3 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Sunitinib (Pan-TK inhibitor);Tumor_type=Gastrointestinal stromal|Gastrointestinal stromal|Gastrointestinal stromal|Gastrointestinal stromal|Gastrointestinal stromal
chr4	55144547	55144547	C	T	Biomarker=PDGFRA:T674I;Evidence_level=Case report;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Hyper eosinophilic advanced snydrome
chr15	88476265	88476265	C	T	Biomarker=NTRK3:G623R;Evidence_level=Pre-clinical|Case report;Association=Resistant|Responsive;Drug=Larotrectinib (Topomyosine kinase inhibitor)|novel TRK inhibitors;Tumor_type=Any cancer type|Any cancer type
chr3	3215822	3215822	G	A	Biomarker=CRBN:Q100*|CRBN oncogenic mutation;Evidence_level=Case report|Case report|Case report|Case report;Association=Resistant|Resistant|Resistant|Resistant;Drug=Lenalidomide (Immunomodulator)|Lenalidomide (Immunomodulator)|Pomalidomide (Immunomodulator)|Pomalidomide (Immunomodulator);Tumor_type=Myeloma|Myeloma|Myeloma|Myeloma
chr3	3195747	3195747	C	T	Biomarker=CRBN:R283K|CRBN oncogenic mutation;Evidence_level=Case report|Case report|Case report|Case report;Association=Resistant|Resistant|Resistant|Resistant;Drug=Lenalidomide (Immunomodulator)|Lenalidomide (Immunomodulator)|Pomalidomide (Immunomodulator)|Pomalidomide (Immunomodulator);Tumor_type=Myeloma|Myeloma|Myeloma|Myeloma
chr17	29652933	29652933	A	C	Biomarker=NF1:D1644A|NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Head an neck|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr7	55249091	55249091	T	A	Biomarker=EGFR:C797S;Evidence_level=Early trials;Association=Resistant;Drug=Osimertinib (EGFR inhibitor 3rd gen);Tumor_type=Lung
chr1	115258748	115258748	C	A	Biomarker=NRAS:G12C|NRAS oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Any cancer type|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr4	55144144	55144144	T	C	Biomarker=PDGFRA:V658A;Evidence_level=Pre-clinical;Association=Responsive;Drug=Crenolanib (FLT3 inhibitor);Tumor_type=Cutaneous melanoma
chr4	55141083	55141083	C	T	Biomarker=PDGFRA:P577S;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=Crenolanib (FLT3 inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr4	55152090	55152090	G	A	Biomarker=PDGFRA:R841K;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=Crenolanib (FLT3 inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr4	55152101	55152101	C	T	Biomarker=PDGFRA:H845Y;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=Crenolanib (FLT3 inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr4	55152126	55152126	G	A	Biomarker=PDGFRA:G853D;Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Responsive;Drug=Crenolanib (FLT3 inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma
chr10	43613899	43613899	T	A	Biomarker=RET:I788N;Evidence_level=Pre-clinical;Association=Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Lung adenocarcinoma
chr7	55249094	55249094	C	A	Biomarker=EGFR:L798I;Evidence_level=Case report;Association=Resistant;Drug=Rociletinib (EGFR inhibitor);Tumor_type=Lung adenocarcinoma
chr19	18271909	18271909	C	T	Biomarker=PIK3R2:A171V;Evidence_level=Pre-clinical;Association=Responsive;Drug=MTOR inhibitors;Tumor_type=Endometrium
chr19	18278061	18278061	A	G	Biomarker=PIK3R2:N561D;Evidence_level=Pre-clinical;Association=Responsive;Drug=MTOR inhibitors;Tumor_type=Endometrium
chr10	43609950	43609950	C	G	Biomarker=RET:C634W|RET (618_620_634_768_791_891_918_C634W_M918T);Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=RET inhibitors|Cabozantinib (Pan-kinase inhibitor)|Sunitinib (Pan-TK inhibitor)|Vandetanib (Pan-TK inhibitor);Tumor_type=Thyroid|Thyroid|Thyroid|Thyroid carcinoma
chr10	43617416	43617416	T	C	Biomarker=RET:M918T|RET (618_620_634_768_791_891_918_C634W_M918T);Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=RET inhibitors|Cabozantinib (Pan-kinase inhibitor)|Sunitinib (Pan-TK inhibitor)|Vandetanib (Pan-TK inhibitor);Tumor_type=Thyroid|Thyroid|Thyroid|Thyroid carcinoma
chr2	198266834	198266834	T	C	Biomarker=SF3B1:K700E;Evidence_level=Pre-clinical;Association=Responsive;Drug=Spliceosome inhibitors;Tumor_type=Any cancer type
chr2	198267359	198267359	C	G	Biomarker=SF3B1:K666N;Evidence_level=Pre-clinical;Association=Responsive;Drug=Spliceosome inhibitors;Tumor_type=Any cancer type
chr7	128851596	128851596	C	G	Biomarker=SMO:P641A;Evidence_level=Case report;Association=Responsive;Drug=Vismodegib (SHH inhibitor);Tumor_type=Lung
chr19	1220489	1220489	C	G	Biomarker=STK11:D194E|STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Everolimus (MTOR inhibitor)|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Pancreas|Lung adenocarcinoma
chr15	66774131	66774131	G	A	Biomarker=MAP2K1:E203K|MAP2K1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|Vemurafenib (BRAF inhibitor);Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr15	66727453	66727453	A	G	Biomarker=MAP2K1:K57E|MAP2K1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|Vemurafenib (BRAF inhibitor);Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr17	7577538	7577538	C	T	Biomarker=TP53:R248Q|TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|HSP90 inhibitors|HSP90 inhibitors|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Any cancer type|Any cancer type|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578406	7578406	C	T	Biomarker=TP53:R175H|TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|HSP90 inhibitors|HSP90 inhibitors|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Any cancer type|Any cancer type|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr6	18143955	18143955	C	G	Biomarker=TPMT:A80P;Evidence_level=FDA guidelines|FDA guidelines|FDA guidelines;Association=Increased Toxicity (Ototoxicity)|Increased Toxicity (Myelosupression)|Increased Toxicity (Myelosupression);Drug=Cisplatin (Chemotherapy)|Mercaptopurine (Purine analog)|Thioguanine (Guanine analog);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr6	18130918	18130918	T	C	Biomarker=TPMT:Y240C;Evidence_level=FDA guidelines|FDA guidelines|FDA guidelines;Association=Increased Toxicity (Ototoxicity)|Increased Toxicity (Myelosupression)|Increased Toxicity (Myelosupression);Drug=Cisplatin (Chemotherapy)|Mercaptopurine (Purine analog)|Thioguanine (Guanine analog);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr6	18139228	18139228	C	T	Biomarker=TPMT:A154T;Evidence_level=FDA guidelines|FDA guidelines|FDA guidelines;Association=Increased Toxicity (Ototoxicity)|Increased Toxicity (Myelosupression)|Increased Toxicity (Myelosupression);Drug=Cisplatin (Chemotherapy)|Mercaptopurine (Purine analog)|Thioguanine (Guanine analog);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr6	18134115	18134115	G	C	Biomarker=TPMT:A167G;Evidence_level=FDA guidelines|FDA guidelines|FDA guidelines;Association=Increased Toxicity (Ototoxicity)|Increased Toxicity (Myelosupression)|Increased Toxicity (Myelosupression);Drug=Cisplatin (Chemotherapy)|Mercaptopurine (Purine analog)|Thioguanine (Guanine analog);Tumor_type=Any cancer type|Any cancer type|Any cancer type
chr16	2130300	2130300	C	T	Biomarker=TSC2:Q1178*|TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines|Case report;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma|Thyroid carcinoma
chr16	2100458	2100458	G	A	Biomarker=TSC2:E66K|TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines|Case report;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma|Endometrium
chr7	128849189	128849189	G	C	Biomarker=SMO:D473H;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=Vismodegib (SHH inhibitor)|Vismodegib (SHH inhibitor);Tumor_type=Medulloblastoma|Basal cell carcinoma
chr2	234669144	234669144	G	A	Biomarker=UGT1A1:G71R;Evidence_level=FDA guidelines|FDA guidelines;Association=Increased Toxicity|Increased Toxicity (Hyperbilirubinemia);Drug=Irinotecan (TOPO1 inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Any cancer type|Any cancer type
chr2	234669619	234669619	C	A	Biomarker=UGT1A1:P229Q;Evidence_level=FDA guidelines|FDA guidelines;Association=Increased Toxicity|Increased Toxicity (Hyperbilirubinemia);Drug=Irinotecan (TOPO1 inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen);Tumor_type=Any cancer type|Any cancer type
chr7	128849190	128849190	A	G	Biomarker=SMO:D473G;Evidence_level=Case report;Association=Resistant;Drug=Vismodegib (SHH inhibitor);Tumor_type=Basal cell carcinoma
chr7	128850341	128850341	G	T	Biomarker=SMO:W535L;Evidence_level=Case report;Association=Resistant;Drug=Vismodegib (SHH inhibitor);Tumor_type=Basal cell carcinoma
chr7	128846398	128846398	C	T	Biomarker=SMO:L412F;Evidence_level=Case report;Association=Resistant;Drug=Vismodegib (SHH inhibitor);Tumor_type=Basal cell carcinoma
chr7	128845546	128845546	G	T	Biomarker=SMO:W281C;Evidence_level=Case report;Association=Resistant;Drug=Vismodegib (SHH inhibitor);Tumor_type=Basal cell carcinoma
chr7	128849201	128849201	C	G	Biomarker=SMO:Q477E;Evidence_level=Case report;Association=Resistant;Drug=Vismodegib (SHH inhibitor);Tumor_type=Basal cell carcinoma
chr7	128850226	128850226	G	T	Biomarker=SMO:G497W;Evidence_level=Case report;Association=Resistant;Drug=Vismodegib (SHH inhibitor);Tumor_type=Basal cell carcinoma
chr2	29419650	29419650	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29420497	29420497	C	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29432655	29432655	T	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29432664	29432664	C	A	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29432681	29432683	TCC	GCT	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29436858	29436858	G	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29436860	29436860	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29436875	29436875	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29436920	29436920	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443589	29443589	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443600	29443600	G	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443600	29443601	GA	CG	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443610	29443610	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443615	29443615	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443624	29443624	A	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443630	29443630	A	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443679	29443679	C	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443685	29443685	T	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443695	29443695	G	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443695	29443695	G	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443696	29443696	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443696	29443696	A	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443697	29443697	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29443697	29443697	A	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445213	29445213	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445216	29445216	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445216	29445216	A	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445228	29445228	A	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445258	29445258	C	A	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445270	29445270	A	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445273	29445273	G	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445418	29445418	G	A	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445449	29445451	CCC	GCT	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445465	29445465	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29445469	29445469	G	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29446296	29446296	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29446376	29446376	T	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29446382	29446382	T	A	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29451923	29451923	C	T	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29474094	29474094	T	C	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr2	29519781	29519781	A	G	Biomarker=ALK oncogenic mutation;Evidence_level=Clinical trials;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Non-small cell lung
chr5	112090657	112090657	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112102034	112102037	ACAA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112102884	112102884	A	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112102953	112102953	T	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112111325	112111325	G	C	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112111326	112111326	G	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112111329	112111330	AT	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112111356	112111356	A	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112116592	112116592	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112128143	112128143	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112128191	112128191	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112137038	112137038	A	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112151204	112151204	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112151261	112151261	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112151282	112151282	G	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154663	112154663	-	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154723	112154723	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154801	112154801	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154830	112154830	T	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154921	112154922	AA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154942	112154942	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112154991	112154991	G	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112162896	112162896	T	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112164585	112164585	G	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112164586	112164586	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112170789	112170789	-	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112170822	112170822	C	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173278	112173278	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173295	112173295	C	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173656	112173656	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173704	112173704	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173838	112173841	TAGA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173854	112173855	GA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173917	112173917	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112173970	112173970	-	GTGTCAG	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174022	112174022	G	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174096	112174096	C	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174096	112174096	C	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174096	112174096	C	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174262	112174262	G	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174368	112174368	A	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174379	112174379	A	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174453	112174453	C	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174474	112174478	ACAAA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174490	112174490	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174493	112174496	TCAA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174551	112174552	TC	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174631	112174631	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174650	112174650	G	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174762	112174765	GAGA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174763	112174763	A	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174763	112174763	-	GA	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174777	112174778	TA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112174893	112174893	C	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175098	112175099	AT	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175121	112175121	T	G	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175207	112175207	G	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175211	112175211	T	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175212	112175215	AAAA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175218	112175222	AAAGA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175219	112175238	AAGATTGGAACTAGGTCAGC	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175219	112175229	AAGATTGGAAC	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175273	112175273	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175303	112175303	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175390	112175390	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175423	112175423	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175426	112175426	G	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175466	112175466	C	A	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175507	112175507	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175576	112175576	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175639	112175639	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175687	112175691	GGACC	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175763	112175763	-	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175912	112175912	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175960	112175961	AT	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112175960	112175967	ATTGATTC	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112176115	112176118	ACCA	TAC	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112176166	112176166	A	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112176781	112176784	TGAA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112177048	112177048	T	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112177227	112177230	ACAA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112177664	112177667	TCTA	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112177674	112177674	C	-	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr5	112178000	112178000	C	T	Biomarker=APC oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chrX	47426120	47426120	T	A	Biomarker=ARAF oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chrX	47426120	47426120	T	G	Biomarker=ARAF oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chrX	47426121	47426121	C	T	Biomarker=ARAF oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chrX	47426130	47426130	A	T	Biomarker=ARAF oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chrX	47426719	47426719	G	A	Biomarker=ARAF oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chrX	47426806	47426806	T	C	Biomarker=ARAF oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=BRAF inhibitor + EGFR mAb inhibitors|BRAF inhibitor + MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Colorectal adenocarcinoma
chr11	108098352	108098352	A	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098352	108098352	A	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098353	108098353	T	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098533	108098533	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098568	108098571	TTCA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098581	108098581	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098584	108098584	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108098600	108098600	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108099956	108099956	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108100002	108100002	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108106433	108106433	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108106443	108106443	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108106446	108106446	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108106543	108106547	TCTCA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108114696	108114696	C	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108114721	108114721	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108114732	108114733	TA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108115569	108115572	CCTC	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108115594	108115594	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108115642	108115642	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108115754	108115754	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108117816	108117819	GAAA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108117841	108117841	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108119704	108119704	C	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108119752	108119752	G	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108119829	108119829	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121441	108121441	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121482	108121483	TG	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121521	108121521	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121531	108121531	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121547	108121547	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121594	108121595	AA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121616	108121616	C	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108121756	108121757	GA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108122693	108122693	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108123620	108123620	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108123641	108123641	T	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108124740	108124740	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108126946	108126946	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108128241	108128242	CT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108128334	108128334	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108129762	108129762	C	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108137932	108137932	-	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108137979	108137979	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108137994	108137994	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108139218	108139221	GTGT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108139252	108139252	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108139287	108139287	T	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108141832	108141832	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108141834	108141834	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108141849	108141851	TTC	GCCAA	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108141864	108141868	AACCA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108141874	108141874	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108141874	108141874	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108142021	108142021	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108142105	108142105	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108142133	108142133	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108143447	108143447	A	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108143540	108143542	ATC	TGAT	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108150237	108150237	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108150282	108150282	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108150302	108150302	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108150305	108150305	C	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108150314	108150317	TCAG	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108150321	108150321	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108151845	108151845	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108151895	108151895	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108153486	108153487	TT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108153487	108153487	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108153572	108153576	TTATT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108154953	108154953	G	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108154961	108154963	TAT	CA	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108154967	108154967	G	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108154986	108154986	-	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155009	108155009	G	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155043	108155043	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155100	108155100	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155102	108155102	G	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155138	108155138	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155187	108155187	T	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108155201	108155201	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108158325	108158325	A	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108158385	108158385	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108158414	108158414	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108159736	108159736	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108159792	108159792	A	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108159821	108159821	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108160451	108160455	AAAAA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108160462	108160462	T	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108160465	108160465	G	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108164052	108164052	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108164206	108164206	T	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108165729	108165729	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108168042	108168042	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108170479	108170479	G	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108172397	108172397	-	AT	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108172487	108172487	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108172506	108172506	C	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108173656	108173656	G	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108178660	108178660	-	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108180889	108180889	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108180915	108180915	G	CCT	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108181014	108181014	A	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108181017	108181021	AAAAG	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108181032	108181032	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108181034	108181034	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108183151	108183151	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108186638	108186638	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108186742	108186742	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108188129	108188129	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108188227	108188227	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108190735	108190735	-	CT	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108190766	108190778	GAAAGTCTCAAAT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108190768	108190768	-	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108196136	108196136	-	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108198392	108198392	-	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108198396	108198399	TACA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108199754	108199754	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108199929	108199929	T	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108201089	108201089	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108201098	108201099	TC	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108202172	108202175	GAGA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108202604	108202604	A	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108202764	108202764	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108203537	108203537	-	GA	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108203613	108203613	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108204636	108204636	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108204682	108204682	-	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108205831	108205831	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108206605	108206605	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108206624	108206624	-	AA	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108206671	108206674	ACTA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108206684	108206688	ATAAG	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108206686	108206686	A	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108213985	108213997	TGGTGCACAGGAA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108214047	108214047	A	TT	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108214075	108214084	TTTCAGTGCC	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108214077	108214077	T	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108214103	108214106	GTGA	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216483	108216483	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216482	108216482	-	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216524	108216524	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216526	108216526	-	AA	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216545	108216545	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216556	108216556	C	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108216637	108216637	T	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108218030	108218030	A	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108218046	108218046	T	G	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108224608	108224608	G	A	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108224608	108224608	G	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108224608	108224608	G	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108225584	108225585	CT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108225586	108225587	GT	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108235900	108235900	A	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108235935	108235935	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108235946	108235946	G	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108236051	108236051	G	C	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108236062	108236062	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108236086	108236086	C	T	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr11	108236176	108236176	C	-	Biomarker=ATM oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=ATR inhibitors|DNA-PKc inhibitors|PARP inhibitors|Cisplatin (Chemotherapy)|Olaparib (PARP inhibitor)|Temozolomide (Chemotherapy);Tumor_type=Colorectal adenocarcinoma|Lymphoma|Stomach|Bladder|Stomach;Prostate adenocarcinoma|Glioma
chr15	45003745	45003745	A	G	Biomarker=B2M oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 Ab inhibitors;Tumor_type=Cutaneous melanoma
chr15	45003746	45003746	T	A	Biomarker=B2M oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 Ab inhibitors;Tumor_type=Cutaneous melanoma
chr15	45003746	45003746	T	C	Biomarker=B2M oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 Ab inhibitors;Tumor_type=Cutaneous melanoma
chr15	45003746	45003746	T	G	Biomarker=B2M oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 Ab inhibitors;Tumor_type=Cutaneous melanoma
chr15	45003747	45003747	G	C	Biomarker=B2M oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 Ab inhibitors;Tumor_type=Cutaneous melanoma
chr3	52436620	52436620	T	A	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52441237	52441237	C	A	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52441262	52441262	A	T	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52442065	52442065	G	T	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52442077	52442078	CA	GC	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52442078	52442078	A	T	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52442504	52442504	A	C	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr3	52442606	52442606	T	A	Biomarker=BAP1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=EZH2 inhibitors|HDAC inhibitors|PARP inhibitors;Tumor_type=Mesothelioma|Cutaneous melanoma|Renal;Any cancer type
chr17	41197726	41197726	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197728	41197728	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197729	41197729	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197728	41197728	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197760	41197760	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197760	41197760	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197764	41197764	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197765	41197765	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197765	41197766	CT	GC	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197774	41197774	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197776	41197776	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197778	41197778	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197778	41197778	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197781	41197781	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197783	41197783	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197784	41197784	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197789	41197789	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197790	41197790	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197808	41197815	TCTGCCCA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41197813	41197820	CCAATTGC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199659	41199659	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199674	41199674	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199683	41199683	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199682	41199682	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199693	41199693	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199695	41199695	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199698	41199698	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199702	41199702	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199707	41199707	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41199719	41199719	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201157	41201157	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201159	41201159	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201179	41201179	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201181	41201181	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201181	41201181	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201181	41201185	CCACA	TCACT	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201191	41201191	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201198	41201198	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201205	41201205	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41201209	41201209	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203078	41203078	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203088	41203088	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203088	41203088	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203088	41203089	AT	TC	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203094	41203094	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203093	41203093	-	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203101	41203102	GC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203103	41203103	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203115	41203115	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203121	41203121	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203124	41203124	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203130	41203130	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203131	41203131	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203135	41203135	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41203135	41203135	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209068	41209068	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209076	41209080	TCCTG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209078	41209080	CTG	ACA	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209081	41209081	-	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209088	41209088	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209091	41209091	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209092	41209092	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209094	41209094	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209095	41209095	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209100	41209100	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209110	41209110	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209119	41209119	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209124	41209124	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209129	41209129	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209130	41209130	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209130	41209130	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209131	41209131	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209133	41209133	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209134	41209134	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209139	41209139	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209139	41209139	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209145	41209145	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209146	41209146	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41209154	41209154	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215349	41215349	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215349	41215349	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215364	41215364	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215370	41215373	CTTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215378	41215378	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215389	41215389	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215390	41215390	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215390	41215390	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215390	41215390	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215389	41215389	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215890	41215890	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215898	41215898	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215899	41215899	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215900	41215900	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215902	41215902	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215905	41215905	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215907	41215907	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215908	41215908	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215920	41215920	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215920	41215920	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215926	41215926	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215929	41215929	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215932	41215932	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215934	41215934	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215934	41215934	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215935	41215935	T	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215936	41215936	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215939	41215939	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215939	41215939	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215945	41215945	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215947	41215947	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215947	41215947	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215948	41215948	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215954	41215954	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215957	41215957	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41215963	41215963	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219624	41219624	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219625	41219625	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219625	41219625	C	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219627	41219627	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219627	41219627	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219633	41219633	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219633	41219633	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219639	41219641	ACA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219641	41219641	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219642	41219642	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219645	41219645	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219646	41219646	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219664	41219664	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219669	41219672	GTTA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219672	41219672	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219713	41219713	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41219714	41219714	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222952	41222952	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222961	41222961	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222964	41222964	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222967	41222967	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222974	41222974	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222976	41222976	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41222997	41222997	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223028	41223028	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223049	41223049	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223063	41223063	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223097	41223097	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223132	41223132	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223240	41223240	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223242	41223242	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41223253	41223253	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226347	41226347	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226347	41226347	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226348	41226348	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226368	41226371	TAAG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226367	41226367	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226410	41226410	-	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226411	41226411	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226420	41226420	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226500	41226500	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226499	41226499	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41226515	41226515	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228505	41228505	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228505	41228505	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228515	41228515	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228529	41228529	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228588	41228588	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228596	41228598	TAG	AA	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228600	41228600	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228600	41228600	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228610	41228610	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41228617	41228617	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234420	41234420	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234424	41234424	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234439	41234439	-	TTCT	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234451	41234451	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234528	41234528	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234529	41234530	CA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234556	41234556	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41234558	41234558	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41242960	41242960	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41242963	41242963	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41242982	41242983	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41242987	41242988	AG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243017	41243018	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243028	41243029	TC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243029	41243029	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243047	41243047	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243051	41243051	T	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243451	41243451	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243482	41243485	GATT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243508	41243509	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243511	41243514	TCTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243514	41243514	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243533	41243533	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243579	41243580	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243611	41243611	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243640	41243640	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243653	41243653	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243655	41243655	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243675	41243675	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243689	41243692	CACT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243707	41243707	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243731	41243731	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243779	41243780	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243783	41243784	GT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243784	41243784	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243788	41243789	TA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243788	41243788	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243794	41243797	GACA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243800	41243800	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243830	41243830	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243838	41243838	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243849	41243853	TTTAC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243877	41243877	-	GAAG	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243878	41243878	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243884	41243884	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243887	41243887	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243891	41243891	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243899	41243899	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243920	41243920	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243922	41243922	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243929	41243929	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243941	41243941	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243950	41243950	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41243967	41243967	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244021	41244021	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244057	41244057	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244059	41244069	AGTATCTTCCT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244063	41244063	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244064	41244073	CTTCCTTTAT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244067	41244067	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244106	41244106	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244148	41244148	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244183	41244184	GT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244196	41244196	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244217	41244220	GCTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244223	41244223	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244225	41244226	AT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244269	41244269	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244291	41244291	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244321	41244322	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244370	41244370	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244391	41244391	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244412	41244421	CATTAATATT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244436	41244436	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244443	41244443	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244482	41244482	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244496	41244496	-	CTCAT	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244505	41244505	-	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244518	41244519	AG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244540	41244541	AA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244546	41244546	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244552	41244553	AG	TA	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244560	41244560	-	TT	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244585	41244585	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244604	41244604	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244608	41244608	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244610	41244610	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244614	41244614	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244627	41244627	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244663	41244663	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244681	41244685	GATGA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244684	41244684	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244712	41244714	TAC	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244740	41244743	ATCT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244779	41244782	AACT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244786	41244786	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244804	41244805	GA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244820	41244823	GATT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244824	41244824	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244826	41244826	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244839	41244839	-	AT	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244863	41244863	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244865	41244865	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244867	41244868	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244869	41244872	CTTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244893	41244894	GA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244894	41244894	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244913	41244913	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244929	41244929	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244945	41244945	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244955	41244955	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41244957	41244957	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245003	41245003	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245034	41245034	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245073	41245073	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245092	41245092	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245118	41245118	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245136	41245137	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245141	41245142	TC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245146	41245147	CA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245151	41245154	ATTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245159	41245159	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245159	41245160	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245189	41245189	-	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245210	41245210	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245215	41245215	-	AC	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245220	41245220	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245235	41245235	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245249	41245249	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245255	41245255	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245277	41245277	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245332	41245332	-	AA	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245334	41245334	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245338	41245339	GT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245351	41245355	CTTCT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245390	41245390	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245410	41245410	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245416	41245417	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245438	41245439	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245479	41245480	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245480	41245480	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245492	41245492	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245504	41245504	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245513	41245513	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245530	41245530	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245531	41245531	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245549	41245549	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245584	41245584	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245588	41245588	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245594	41245594	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245593	41245593	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245595	41245598	CTTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245598	41245598	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245628	41245628	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245632	41245632	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245670	41245670	-	ACTA	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245689	41245689	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245724	41245727	CTTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245739	41245739	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245755	41245755	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245759	41245759	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245792	41245792	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245861	41245861	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245972	41245972	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41245993	41245993	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246000	41246000	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246031	41246031	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246038	41246038	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246044	41246048	ATTTA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246060	41246060	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246072	41246072	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246077	41246077	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246103	41246106	ATTA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246111	41246111	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246164	41246164	C	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246191	41246192	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246207	41246208	AA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246260	41246260	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246291	41246291	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246308	41246308	-	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246360	41246360	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246423	41246423	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246432	41246432	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246458	41246468	GATTCTCTGAG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246482	41246482	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246494	41246494	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246536	41246536	T	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246537	41246537	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246566	41246567	AT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246586	41246586	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246612	41246612	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246619	41246619	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246653	41246654	CA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246679	41246679	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246698	41246698	-	TAATGAG	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246702	41246705	TGAG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246730	41246730	-	GCTCCACATG	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246750	41246751	AA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246765	41246765	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246785	41246785	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246813	41246813	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246851	41246852	CA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246866	41246866	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41246873	41246873	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251791	41251791	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251825	41251825	G	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251826	41251826	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251834	41251834	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251850	41251850	T	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251853	41251853	-	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251855	41251856	CA	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41251872	41251873	AG	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41256153	41256153	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41256163	41256163	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41256190	41256190	G	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41256244	41256247	ATTT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41256255	41256255	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41256277	41256277	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258474	41258474	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258484	41258485	AT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258493	41258493	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258494	41258494	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258495	41258495	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258495	41258495	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258497	41258497	A	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258504	41258504	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258525	41258525	G	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258542	41258542	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258546	41258546	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41258551	41258551	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267743	41267744	TT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267746	41267746	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267746	41267746	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267755	41267755	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267761	41267761	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267762	41267763	AC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267767	41267767	G	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267779	41267779	T	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41267797	41267797	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276034	41276035	CA	GC	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276035	41276045	AGATGGGACAC	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276043	41276043	C	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276044	41276044	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276047	41276048	CT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276047	41276047	-	T	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276061	41276061	A	G	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276070	41276070	A	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276074	41276077	CATT	-	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276111	41276111	C	A	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276112	41276112	A	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr17	41276113	41276113	T	C	Biomarker=BRCA1 oncogenic mutation;Evidence_level=Early trials|Case report|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PARP inhibitors|WEE1 inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Pancreas|Any cancer type|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Ovary|Breast adenocarcinoma
chr13	32890598	32890598	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890599	32890599	T	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890599	32890599	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890600	32890600	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890623	32890623	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890648	32890649	AC	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890665	32890665	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32890666	32890666	T	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893217	32893217	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893291	32893291	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893342	32893342	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893396	32893396	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893408	32893409	CT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893420	32893420	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32893435	32893435	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32899303	32899303	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32899321	32899321	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900236	32900236	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900241	32900241	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900282	32900286	AGTCA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900288	32900288	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900377	32900377	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900635	32900635	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900636	32900636	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900639	32900639	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900691	32900691	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900693	32900694	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900706	32900706	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900712	32900715	TAGC	AGG	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900729	32900729	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900736	32900736	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900750	32900750	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900751	32900751	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32900752	32900752	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32903606	32903607	GT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32903617	32903617	-	GATA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905103	32905106	TGAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905129	32905132	ACAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905130	32905131	CA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905141	32905142	CA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905145	32905149	TCAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905146	32905146	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905152	32905153	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32905148	32905149	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906414	32906414	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906506	32906514	AACAGTTGT	GATACTTCAG	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906545	32906546	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906570	32906570	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906644	32906644	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906668	32906668	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906718	32906718	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906753	32906753	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906777	32906777	-	TACC	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906804	32906804	-	TTAG	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906803	32906803	-	TTAG	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906820	32906820	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906834	32906834	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906853	32906853	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906872	32906872	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906876	32906876	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906880	32906880	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906911	32906912	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906923	32906924	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32906925	32906928	AAGA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907004	32907005	AG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907014	32907014	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907026	32907026	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907043	32907046	TCAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907061	32907061	-	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907111	32907112	AG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907167	32907167	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907185	32907186	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907257	32907257	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907269	32907269	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907285	32907285	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907363	32907363	T	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907369	32907369	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907370	32907374	GAAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907378	32907381	ATAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907388	32907391	TTAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907411	32907415	CTTAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907415	32907415	T	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907415	32907415	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907428	32907428	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907427	32907427	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907432	32907434	CGA	TTT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907447	32907447	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907470	32907470	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907470	32907470	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32907525	32907525	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910421	32910421	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910452	32910452	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910551	32910555	GATTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910584	32910584	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910703	32910703	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910716	32910716	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910804	32910804	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910821	32910821	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910831	32910831	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910868	32910868	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910871	32910871	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910901	32910901	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910918	32910918	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910927	32910927	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910971	32910971	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32910986	32910986	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911009	32911009	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911061	32911061	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911095	32911095	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911104	32911104	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911145	32911148	GACA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911184	32911188	AGGAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911193	32911193	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911300	32911303	ACAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911300	32911300	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911310	32911310	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911322	32911322	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911328	32911329	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911391	32911392	CT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911410	32911410	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911448	32911448	-	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911448	32911448	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911471	32911471	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911501	32911502	CA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911502	32911502	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911567	32911568	GA	TT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911595	32911595	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911601	32911601	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911650	32911650	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911652	32911655	GATA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911658	32911658	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911659	32911662	AAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911662	32911666	AGAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911664	32911664	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911668	32911669	TG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911687	32911690	TAAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911687	32911687	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911718	32911722	GTAGT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911755	32911755	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911788	32911788	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911811	32911811	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911843	32911843	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911845	32911847	TAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911850	32911850	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911854	32911854	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911854	32911854	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911857	32911857	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911902	32911902	-	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32911904	32911904	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912037	32912038	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912091	32912092	GT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912172	32912173	TG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912181	32912181	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912199	32912199	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912209	32912209	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912236	32912239	TGAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912242	32912242	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912277	32912277	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912312	32912315	AAGA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912327	32912327	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912339	32912340	GT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912352	32912352	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912351	32912351	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912414	32912414	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912459	32912459	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912466	32912466	-	TGCT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912492	32912493	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912550	32912554	AAACG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912584	32912585	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912603	32912603	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912603	32912603	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912630	32912630	-	TT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912655	32912656	CT	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912660	32912661	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912668	32912668	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912680	32912680	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912703	32912707	CAAAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912738	32912738	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912750	32912750	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912767	32912767	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912769	32912769	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912775	32912775	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912817	32912817	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912890	32912894	ACATT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912897	32912901	GACAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912941	32912941	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912948	32912951	GTTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912963	32912966	CTGA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912969	32912970	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32912970	32912973	AAAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913007	32913017	CTTCCAGGGAC	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913043	32913046	AGAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913044	32913044	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913078	32913078	-	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913080	32913080	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913123	32913123	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913122	32913122	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913130	32913130	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913139	32913142	AGAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913182	32913182	-	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913204	32913205	AG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913272	32913272	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913316	32913317	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913313	32913315	TGA	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913321	32913322	TG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913368	32913369	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913381	32913381	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913405	32913405	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913428	32913429	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913428	32913431	GAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913432	32913433	CA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913439	32913440	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913457	32913457	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913527	32913527	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913565	32913565	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913564	32913564	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913608	32913611	AATA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913622	32913625	TGTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913638	32913641	TATG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913649	32913649	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913651	32913651	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913662	32913662	-	TA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913687	32913687	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913709	32913715	TTTAAGT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913709	32913712	TTTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913713	32913717	AGTAA	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913714	32913717	GTAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913729	32913729	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913771	32913771	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913795	32913796	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913842	32913843	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913842	32913842	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913845	32913845	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913853	32913853	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913855	32913855	-	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913878	32913879	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913902	32913903	GT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913914	32913915	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913926	32913926	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913931	32913931	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913946	32913946	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913962	32913963	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913962	32913962	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913974	32913978	AAATT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32913987	32913987	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914034	32914034	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914049	32914049	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914052	32914053	GT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914061	32914065	GAAAC	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914068	32914071	TTAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914070	32914070	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914075	32914075	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914074	32914074	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914077	32914080	TGAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914101	32914102	TC	AG	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914106	32914106	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914108	32914112	AGTAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914113	32914116	TTAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914118	32914118	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914123	32914123	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914127	32914127	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914133	32914136	AAAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914136	32914139	TCAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914137	32914137	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914147	32914147	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914148	32914148	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914172	32914172	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914174	32914174	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914174	32914174	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914206	32914206	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914214	32914215	CT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914255	32914255	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914274	32914274	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914283	32914283	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914288	32914289	TA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914291	32914294	CCAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914320	32914320	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914343	32914346	AGTT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914349	32914349	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914354	32914355	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914356	32914356	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914356	32914356	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914401	32914401	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914417	32914417	T	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914425	32914425	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914438	32914438	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914514	32914514	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914515	32914515	-	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914525	32914526	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914529	32914529	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914560	32914564	ACCAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914562	32914562	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914570	32914570	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914574	32914578	GAAGA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914582	32914582	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914589	32914589	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914616	32914616	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914647	32914647	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914693	32914693	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914708	32914708	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914718	32914721	GTTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914759	32914761	GCA	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914758	32914758	-	GCAT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914767	32914768	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914800	32914800	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914823	32914824	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914840	32914840	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914858	32914858	-	GAAA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914864	32914864	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914885	32914888	ATTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914897	32914901	CTTAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914900	32914906	AAATGTT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914935	32914935	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914938	32914942	TTAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914938	32914938	-	TA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914950	32914950	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914960	32914961	TC	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914967	32914967	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32914978	32914981	ACAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915023	32915026	TCAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915039	32915039	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915057	32915057	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915083	32915084	TG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915092	32915093	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915093	32915093	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915126	32915129	TGTT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915132	32915132	-	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915136	32915139	ACTC	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915154	32915154	-	AAAG	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915177	32915177	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915194	32915194	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915195	32915196	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915249	32915250	CT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915308	32915312	AAGAG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915325	32915329	TCTTA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32915328	32915329	TA	CTTTGTGGTAAGTTT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32920970	32920973	TAAA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32920978	32920978	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32921033	32921033	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32921033	32921033	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929014	32929014	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929016	32929016	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929059	32929060	CT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929086	32929086	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929141	32929142	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929170	32929170	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929241	32929242	CA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929291	32929291	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929369	32929369	-	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32929404	32929405	AA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32930597	32930597	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32930609	32930609	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32930687	32930687	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32930717	32930717	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32930748	32930748	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32931878	32931878	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32931934	32931935	AG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32931950	32931950	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32931979	32931979	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32932018	32932018	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32932038	32932038	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32932066	32932066	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936708	32936708	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936711	32936711	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936710	32936710	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936726	32936726	T	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936731	32936731	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936733	32936733	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936767	32936771	TTCCT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936788	32936788	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936794	32936794	T	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936800	32936800	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936812	32936812	T	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936830	32936830	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32936830	32936830	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937315	32937315	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937315	32937315	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937318	32937330	ATGATACGGAAAT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937327	32937327	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937362	32937362	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937368	32937368	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937408	32937408	-	TT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937482	32937482	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937504	32937504	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937506	32937506	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937507	32937507	A	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937507	32937507	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937513	32937513	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937513	32937524	GGTATGCTGTTA	TT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937582	32937582	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937586	32937587	GA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937636	32937636	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937653	32937653	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32937671	32937671	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944538	32944538	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944547	32944550	TAAC	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944557	32944557	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944584	32944584	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944601	32944603	TAG	AA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944627	32944627	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944681	32944681	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32944695	32944695	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945092	32945092	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945095	32945095	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945110	32945110	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945129	32945129	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945142	32945143	AG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945180	32945180	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945180	32945180	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945186	32945186	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945189	32945189	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945198	32945198	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32945213	32945213	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953536	32953536	T	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953538	32953538	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953574	32953574	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953577	32953577	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953603	32953603	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953653	32953653	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953653	32953653	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953886	32953888	GTT	AA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953902	32953902	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953911	32953911	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953928	32953928	-	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953937	32953937	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953951	32953951	C	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953958	32953958	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32953974	32953974	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954009	32954009	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954029	32954029	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954050	32954050	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954142	32954142	A	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954153	32954153	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954180	32954180	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954208	32954208	T	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954220	32954221	TT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954222	32954222	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954278	32954278	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32954282	32954283	GG	TA	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968825	32968825	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968831	32968831	G	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968854	32968854	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968863	32968863	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968900	32968900	G	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968921	32968922	AT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968940	32968940	A	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968945	32968945	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968949	32968949	G	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968951	32968951	C	T	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32968972	32968972	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32969004	32969005	GT	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32971055	32971056	TG	AT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32971182	32971182	G	C	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972316	32972316	T	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972321	32972321	-	A	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972349	32972352	TATG	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972378	32972378	C	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972420	32972423	AAGA	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972540	32972540	-	ATTT	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972574	32972574	C	G	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr13	32972595	32972595	A	-	Biomarker=BRCA2 oncogenic mutation;Evidence_level=Early trials|Case report|Early trials|Early trials|FDA guidelines|Early trials|Late trials|Case report|FDA guidelines|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitor + Chemotherapys|PD1 Ab inhibitors|PARP inhibitors (Olaparib_etc)|Olaparib (PARP inhibitor)|Olaparib (PARP inhibitor)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Platinum Agent (Chemotherapy)|Rucaparib (PARP inhibitor)|Veliparib + Cisplatin (PARP inhibitor + Chemotherapy);Tumor_type=Ovary|Cutaneous melanoma|Breast adenocarcinoma|Prostate adenocarcinoma|Ovary|Breast adenocarcinoma|Ovary|Pancreas|Ovary|Breast adenocarcinoma
chr16	68772211	68772211	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68772227	68772227	G	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68835611	68835611	T	-	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68842459	68842459	-	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68844119	68844119	C	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68844172	68844172	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68844181	68844181	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68844193	68844193	G	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68845646	68845646	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68845757	68845757	C	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68846038	68846039	AG	-	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68846047	68846047	A	G	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68846093	68846093	T	-	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68846166	68846166	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68847225	68847225	C	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68849663	68849663	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68849663	68849663	G	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68856041	68856041	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68856093	68856093	C	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68856113	68856113	C	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68857343	68857343	-	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68857364	68857364	C	-	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68857429	68857430	TG	-	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68862107	68862107	G	A	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68862199	68862199	G	T	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr16	68863691	68863691	T	-	Biomarker=CDH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Bicalutamide (AR inhibitor);Tumor_type=Breast adenocarcinoma
chr17	37649051	37649051	G	A	Biomarker=CDK12 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=PARP inhibitors;Tumor_type=Ovary
chr17	37665993	37665993	G	T	Biomarker=CDK12 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=PARP inhibitors;Tumor_type=Ovary
chr17	37667817	37667817	A	G	Biomarker=CDK12 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=PARP inhibitors;Tumor_type=Ovary
chr17	37667840	37667840	G	A	Biomarker=CDK12 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=PARP inhibitors;Tumor_type=Ovary
chr17	37676233	37676233	A	T	Biomarker=CDK12 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=PARP inhibitors;Tumor_type=Ovary
chr12	58144753	58144753	A	-	Biomarker=CDK4 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=LEE011 (CDK4/6 inhibitor);Tumor_type=Liposarcoma;Lymphoma;Any cancer type
chr12	58145430	58145430	C	T	Biomarker=CDK4 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=LEE011 (CDK4/6 inhibitor);Tumor_type=Liposarcoma;Lymphoma;Any cancer type
chr12	58145431	58145431	G	A	Biomarker=CDK4 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=LEE011 (CDK4/6 inhibitor);Tumor_type=Liposarcoma;Lymphoma;Any cancer type
chr12	58145436	58145437	TT	GC	Biomarker=CDK4 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=LEE011 (CDK4/6 inhibitor);Tumor_type=Liposarcoma;Lymphoma;Any cancer type
chr12	12870798	12870798	G	A	Biomarker=CDKN1B oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=CDK2/4 inhibitors;Tumor_type=Any cancer type
chr12	12871170	12871170	C	A	Biomarker=CDKN1B oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=CDK2/4 inhibitors;Tumor_type=Any cancer type
chr9	21970901	21970901	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21970981	21970981	A	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971017	21971017	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971018	21971018	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971018	21971019	GC	AG	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971021	21971021	-	ACG	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971024	21971024	G	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971029	21971029	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971028	21971028	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971036	21971036	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971036	21971036	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971036	21971036	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971057	21971057	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971062	21971062	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971068	21971068	A	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971096	21971096	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971096	21971096	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971098	21971098	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971098	21971098	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971099	21971099	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971107	21971107	T	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971107	21971107	T	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971107	21971120	TCGTGCACGGGTCG	-	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971108	21971108	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971108	21971108	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971108	21971108	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971111	21971111	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971111	21971111	G	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971116	21971116	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971117	21971117	G	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971119	21971119	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971119	21971119	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971120	21971120	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971129	21971129	T	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971138	21971138	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971138	21971138	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971145	21971145	G	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971146	21971146	T	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971146	21971146	T	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971152	21971152	T	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971153	21971153	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971156	21971156	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971159	21971159	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971159	21971159	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971177	21971177	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971179	21971179	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971179	21971180	GC	CT	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971186	21971186	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971188	21971188	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971190	21971190	G	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971191	21971191	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971199	21971199	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971202	21971202	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971202	21971202	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21971208	21971208	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974678	21974678	T	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974679	21974679	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974681	21974681	A	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974684	21974684	G	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974685	21974685	G	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974694	21974694	-	TT	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974721	21974721	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974723	21974723	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974723	21974723	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974724	21974724	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974724	21974724	-	C	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974732	21974732	A	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974756	21974756	C	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974759	21974759	C	T	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974776	21974776	-	GCC	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974780	21974780	A	G	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974782	21974785	CCAG	-	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974793	21974793	-	GGCTCCATGCTGCTCCCCGCCGCC	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	21974860	21974860	C	A	Biomarker=CDKN2A oncogenic mutation;Evidence_level=Case report|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=CDK4/6 inhibitors|CDK4/6 inhibitors|Ilorasertib (AURKA-VEGF inhibitor);Tumor_type=Cutaneous melanoma|Glioma;Any cancer type|Any cancer type
chr9	22006147	22006147	C	T	Biomarker=CDKN2B oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=CDK4/6 inhibitors;Tumor_type=Glioma;Any cancer type
chr9	22008835	22008835	G	T	Biomarker=CDKN2B oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=CDK4/6 inhibitors;Tumor_type=Glioma;Any cancer type
chr9	22008850	22008850	C	A	Biomarker=CDKN2B oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=CDK4/6 inhibitors;Tumor_type=Glioma;Any cancer type
chr9	22008885	22008885	G	T	Biomarker=CDKN2B oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=CDK4/6 inhibitors;Tumor_type=Glioma;Any cancer type
chr22	29083962	29083962	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29085162	29085162	-	TC	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29085176	29085176	C	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29090048	29090048	T	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091121	29091121	-	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091134	29091134	C	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091207	29091207	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091228	29091228	A	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091707	29091707	A	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091745	29091745	A	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091840	29091840	T	C	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091846	29091846	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29091857	29091857	G	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29092973	29092973	G	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29095873	29095873	C	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29095917	29095917	-	C	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29099502	29099502	A	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29106048	29106048	C	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29107974	29107974	C	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29115401	29115401	-	TGAT	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29115411	29115411	C	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29120968	29120968	T	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29120976	29120976	C	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121032	29121032	-	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121052	29121052	A	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121230	29121230	C	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121266	29121266	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121272	29121272	T	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121311	29121311	C	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29121326	29121326	T	C	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130427	29130427	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130431	29130431	C	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130432	29130432	C	T	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130433	29130433	A	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130464	29130464	G	-	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130494	29130494	A	C	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130559	29130559	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr22	29130625	29130625	G	A	Biomarker=CHEK2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr3	41266040	41266040	G	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266064	41266064	G	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266068	41266068	T	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266068	41266118	TTAGTCACTGGCAGCAACAGTCTTACCTGGACTCTGGAATCCATTCTGGTG	-	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266072	41266072	T	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266077	41266100	GGCAGCAACAGTCTTACCTGGACT	-	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266097	41266097	G	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266097	41266097	G	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266097	41266097	G	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266098	41266098	A	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266098	41266098	A	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266100	41266100	T	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266101	41266101	C	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266101	41266101	C	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266101	41266101	C	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266103	41266103	G	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266103	41266103	G	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266104	41266104	G	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266104	41266104	G	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266104	41266104	G	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266107	41266107	T	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266110	41266110	A	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266112	41266112	T	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266112	41266112	T	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266113	41266113	C	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266121	41266121	A	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266121	41266121	A	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266122	41266122	C	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266121	41266121	A	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266122	41266122	C	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266124	41266124	A	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266133	41266133	C	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266136	41266136	T	C	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266136	41266136	T	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266137	41266137	C	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266137	41266137	C	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41266137	41266137	C	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41268766	41268766	A	T	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41274897	41274897	T	A	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr3	41274911	41274911	T	G	Biomarker=CTNNB1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Resistant;Drug=Tankyrase inhibitors;Tumor_type=Colorectal adenocarcinoma
chr2	25457242	25457242	C	A	Biomarker=DNMT3A oncogenic mutation;Evidence_level=FDA guidelines;Association=Responsive;Drug=Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia
chr2	25457242	25457242	C	G	Biomarker=DNMT3A oncogenic mutation;Evidence_level=FDA guidelines;Association=Responsive;Drug=Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia
chr2	25457242	25457242	C	T	Biomarker=DNMT3A oncogenic mutation;Evidence_level=FDA guidelines;Association=Responsive;Drug=Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia
chr2	25457243	25457243	G	A	Biomarker=DNMT3A oncogenic mutation;Evidence_level=FDA guidelines;Association=Responsive;Drug=Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia
chr2	25457243	25457243	G	C	Biomarker=DNMT3A oncogenic mutation;Evidence_level=FDA guidelines;Association=Responsive;Drug=Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia
chr2	25457243	25457243	G	T	Biomarker=DNMT3A oncogenic mutation;Evidence_level=FDA guidelines;Association=Responsive;Drug=Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia
chr17	37866626	37866626	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37866662	37866662	G	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37866707	37866707	G	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37868282	37868282	A	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879583	37879583	C	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879585	37879585	A	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879601	37879602	TT	AA	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879604	37879604	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879658	37879658	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879854	37879854	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879861	37879861	A	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879881	37879881	C	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879881	37879881	C	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37879903	37879903	C	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880219	37880220	TT	CC	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880220	37880234	TGAGGGAAAACACAT	-	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880257	37880257	C	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880262	37880262	A	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880983	37880983	-	ATACGTGATGGC	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880989	37880989	T	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880996	37880996	-	TGT	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880997	37880997	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37880998	37880998	-	TGTGGGCTC	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881000	37881000	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881000	37881000	G	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881001	37881001	T	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881002	37881002	-	GGCTCCCCA	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881001	37881001	-	GGGCTCCCC	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881010	37881010	C	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881018	37881018	T	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881024	37881024	C	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881025	37881025	T	C	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881051	37881051	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881064	37881065	CA	TG	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881078	37881078	T	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881093	37881093	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881105	37881105	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881132	37881132	G	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881324	37881324	T	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881378	37881378	A	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881392	37881392	A	G	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881404	37881404	C	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881440	37881440	C	T	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr17	37881977	37881977	C	A	Biomarker=ERBB2 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive;Drug=Dacomitinib (Pan ERBB inhibitor)|Neratinib (ERBB2 inhibitor)|Tensirolimus (MTOR inhibitor);Tumor_type=Non-small cell lung|Lung adenocarcinoma|Lung adenocarcinoma
chr19	45855507	45855507	G	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45855816	45855816	C	G	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45856015	45856015	G	A	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45856345	45856345	G	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45856346	45856346	T	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45856355	45856355	T	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45856370	45856370	C	T	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45858047	45858047	C	T	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45858929	45858929	C	A	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45860548	45860548	G	A	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45860619	45860619	G	A	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45860626	45860626	G	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45860928	45860928	C	T	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45867584	45867584	C	A	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45867687	45867687	T	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr19	45873425	45873425	T	C	Biomarker=ERCC2 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr16	14021989	14021989	T	C	Biomarker=ERCC4 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Ovary
chr16	14041518	14041518	C	A	Biomarker=ERCC4 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Ovary
chr16	14041810	14041810	C	T	Biomarker=ERCC4 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Ovary
chr16	14042077	14042077	A	G	Biomarker=ERCC4 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Ovary
chr6	152332832	152332832	G	C	Biomarker=ESR1 oncogenic mutation|ESR1 (E380Q_537_538_L536_P535H);Evidence_level=Late trials|Late trials|Case report|Early trials;Association=Responsive|Resistant|Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy)|novel ER degraders (GDC-0810_etc)|Tamoxifen (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma|Breast adenocarcinoma|Breast adenocarcinoma
chr6	152332893	152332893	G	T	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152415537	152415537	T	C	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152415555	152415555	C	G	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419917	152419917	C	A	Biomarker=ESR1 oncogenic mutation|ESR1 (E380Q_537_538_L536_P535H);Evidence_level=Late trials|Late trials|Case report|Early trials;Association=Responsive|Resistant|Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy)|novel ER degraders (GDC-0810_etc)|Tamoxifen (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma|Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419920	152419920	T	A	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419920	152419920	T	C	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419920	152419920	T	G	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419920	152419921	TC	AA	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419922	152419922	T	A	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419923	152419923	A	G	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419926	152419926	A	G	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419940	152419941	AT	GC	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr6	152419943	152419944	CT	GC	Biomarker=ESR1 oncogenic mutation;Evidence_level=Late trials|Late trials;Association=Responsive|Resistant;Drug=Fluvestrant (Hormonal therapy)|Exemestane (Hormonal therapy);Tumor_type=Breast adenocarcinoma|Breast adenocarcinoma
chr16	89815152	89815152	G	A	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89816213	89816213	C	A	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89833576	89833576	G	C	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89849452	89849452	T	C	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89849506	89849506	T	C	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89866018	89866018	A	G	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89871768	89871768	A	C	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr16	89874750	89874751	CA	GC	Biomarker=FANCA oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Olaparib (PARP inhibitor);Tumor_type=Prostate adenocarcinoma
chr9	97864024	97864024	G	A	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	97869496	97869497	AG	-	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	97873771	97873771	-	A	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	97897627	97897627	C	T	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	97912338	97912338	G	A	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	97933395	97933398	CTCT	-	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	97934415	97934420	ATGAGA	T	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	98002957	98002957	G	A	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	98011509	98011509	C	-	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	98011537	98011537	G	A	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr9	98011653	98011653	T	C	Biomarker=FANCC oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=Cisplatin (Chemotherapy);Tumor_type=Bladder
chr4	187509981	187509981	G	A	Biomarker=FAT1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=BET inhibitors;Tumor_type=Head an neck squamous
chr4	187510258	187510258	C	A	Biomarker=FAT1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=BET inhibitors;Tumor_type=Head an neck squamous
chr4	187517769	187517769	G	C	Biomarker=FAT1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=BET inhibitors;Tumor_type=Head an neck squamous
chr4	153244091	153244091	C	T	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153244184	153244184	C	T	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153247244	153247244	C	T	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153247288	153247288	C	A	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153247289	153247289	G	A	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153247365	153247366	TC	AT	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153247366	153247366	C	A	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153247366	153247366	C	T	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153249384	153249384	C	T	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153249385	153249385	G	A	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153249511	153249511	C	T	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153268129	153268129	A	C	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	153332924	153332924	T	C	Biomarker=FBXW7 oncogenic mutation;Evidence_level=Pre-clinical|Late trials;Association=Resistant|Responsive;Drug=Tubulin inhibitors|Steroids;Tumor_type=Any cancer type|Acute lymphoblastic leukemia
chr4	1803564	1803564	C	T	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1805452	1805452	G	A	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1806089	1806089	G	T	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1806092	1806092	A	T	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1806104	1806104	G	T	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1806119	1806119	G	A	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1806126	1806126	G	A	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1806153	1806153	C	A	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807335	1807335	G	C	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807363	1807363	A	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807370	1807370	A	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807371	1807371	C	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807488	1807488	G	A	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807862	1807862	G	A	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807863	1807863	A	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807881	1807881	A	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807889	1807889	A	C	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807889	1807889	A	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807890	1807890	A	C	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807890	1807890	A	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807890	1807890	A	T	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1807891	1807891	G	C	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr4	1808029	1808029	C	G	Biomarker=FGFR3 oncogenic mutation;Evidence_level=Early trials;Association=Responsive;Drug=FGFR inhibitors;Tumor_type=Bladder
chr17	17118378	17118378	C	A	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17118542	17118542	G	C	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17119715	17119715	-	G	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17119779	17119779	G	C	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17120442	17120442	G	A	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17122452	17122452	C	A	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17127355	17127355	G	A	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17129637	17129637	C	T	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr17	17131216	17131216	G	C	Biomarker=FLCN oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=Everolimus (MTOR inhibitor);Tumor_type=Renal
chr11	533466	533466	G	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533467	533467	C	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533552	533552	C	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533553	533553	T	C	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533865	533866	TA	GC	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533873	533873	C	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533873	533873	C	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533873	533874	CT	AC	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533873	533874	CT	TC	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533874	533874	T	C	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533874	533874	T	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533874	533874	T	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533875	533875	G	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533880	533880	G	C	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533881	533881	C	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	533883	533883	G	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534222	534222	G	C	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534241	534241	A	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534259	534259	G	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534285	534285	C	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534285	534285	C	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534286	534286	C	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534286	534286	C	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534286	534286	C	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534288	534288	C	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534288	534288	C	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534288	534288	C	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534289	534289	C	A	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534289	534289	C	G	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr11	534289	534289	C	T	Biomarker=HRAS oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MEK inhibitor +/- MTOR inhibitors|MTOR inhibitors|PI3K pathway inhibitor + MEK inhibitors|Tipifarnib (Farnesyltransferase inhibitor)|Tipifarnib (Farnesyltransferase inhibitor);Tumor_type=Acute myeloid leukemia|Cervix squamous cell|Cervix|Any cancer type|Any cancer type
chr2	209110148	209110148	A	C	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113111	209113112	AC	TT	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113112	209113112	C	A	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113112	209113112	C	G	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113112	209113112	C	T	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113113	209113113	G	A	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113113	209113113	G	C	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113113	209113113	G	T	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113208	209113209	CG	GC	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr2	209113217	209113217	C	T	Biomarker=IDH1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Early trials|Early trials|Early trials;Association=Responsive|Responsive|Responsive|Responsive|Responsive;Drug=BCL2 inhibitors|IDH1 inhibitors|AG-120 (IDH1 inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia|Glioma|Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631837	90631837	C	G	Biomarker=IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631838	90631838	C	A	Biomarker=IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631839	90631839	T	C	Biomarker=IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631934	90631934	C	A	Biomarker=IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631934	90631934	C	T	Biomarker=IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Cholangiocarcinoma|Acute myeloid leukemia
chr15	90631935	90631935	G	A	Biomarker=IDH2 oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Dasatinib (BCR-ABL inhibitor 2nd gen)|Venetoclax (BCL2 inhibitor);Tumor_type=Cholangiocarcinoma|Acute myeloid leukemia
chr1	65303651	65303651	T	C	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65303679	65303679	T	C	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65304242	65304242	A	C	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65304242	65304242	A	G	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65304243	65304243	A	C	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65305399	65305399	A	G	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65306942	65306942	G	A	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65309803	65309803	G	A	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65310503	65310503	T	A	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65310517	65310517	C	T	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65310520	65310520	G	T	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65311203	65311203	C	A	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65312347	65312347	C	A	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65312365	65312365	A	G	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65312375	65312375	T	G	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr1	65312382	65312382	G	A	Biomarker=JAK1 oncogenic mutation|JAK1 (S646F;Evidence_level=Case report|Case report|Pre-clinical;Association=Resistant|Resistant|Responsive;Drug=PD1 inhibitors|PD1 inhibitors|Ruxolitinib (JAK inhibitor);Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma|Acute lymphoblastic leukemia
chr1	65312418	65312418	G	T	Biomarker=JAK1 oncogenic mutation;Evidence_level=Case report|Case report;Association=Resistant|Resistant;Drug=PD1 inhibitors|PD1 inhibitors;Tumor_type=Colorectal adenocarcinoma|Cutaneous melanoma
chr9	5070025	5070025	C	A	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5070026	5070027	AA	CT	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5073742	5073742	G	C	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5073752	5073752	T	G	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5073773	5073773	T	C	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5078360	5078360	A	G	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5078361	5078361	G	A	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5078361	5078361	G	C	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5078362	5078362	A	C	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5078362	5078362	A	T	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr9	5089726	5089726	C	A	Biomarker=JAK2 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=PD1 inhibitors;Tumor_type=Cutaneous melanoma
chr12	25362838	25362838	T	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25368479	25368479	A	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25368490	25368490	A	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378559	25378559	T	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378561	25378561	G	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378562	25378562	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378562	25378562	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378642	25378642	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378643	25378643	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378646	25378646	A	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378647	25378647	T	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25378647	25378647	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380238	25380238	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380247	25380247	A	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380264	25380264	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380267	25380268	TA	GC	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380274	25380274	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380275	25380275	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380275	25380275	T	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380276	25380276	T	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380276	25380276	T	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380276	25380276	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380277	25380277	G	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380277	25380277	G	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380279	25380279	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380280	25380280	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380280	25380280	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380282	25380282	G	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380283	25380283	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25380285	25380285	G	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398218	25398218	G	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398218	25398218	G	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398220	25398220	A	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398224	25398224	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398237	25398237	A	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398254	25398254	T	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398255	25398255	G	C	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398255	25398255	G	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398262	25398262	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398262	25398262	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398266	25398266	G	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398269	25398269	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398279	25398279	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398280	25398281	GC	CT	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398281	25398281	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398281	25398281	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398282	25398282	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398282	25398282	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398282	25398282	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398284	25398284	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398284	25398284	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398284	25398284	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398284	25398285	CC	AA	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398285	25398285	C	A	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398285	25398285	C	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398285	25398285	C	T	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398289	25398289	-	CCA	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr12	25398304	25398304	T	G	Biomarker=KRAS oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|NCCN guidelines|NCCN guidelines|NCCN guidelines|Late trials|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report|Pre-clinical|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Early Trials_Case Report|Pre-clinical;Association=No Responsive|No Responsive|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitor + MEK inhibitors|Selumetinib (MEK inhibitor)|EGFR inhibitors|EGFR mAb inhibitors|EZH2 inhibitors|PI3K pathway inhibitors|Panitumumab (EGFR mAb inhibitor)|Cetuximab (EGFR mAb inhibitor)|EGFR inhibitors|Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)|BET inhibitors|CDK4 inhibitors|CDK4/6 inhibitor + MEK inhibitors|CDK4/6 inhibitor + MEK inhibitors|EGFR mAb inhibitor + MEK inhibitors|ERK inhibitors|FAK inhibitors|FAS inhibitors|FAS inhibitors|HSP90 inhibitor (in combination)s|JAK/TBK1/IKKε inhibitors|MEK inhibitor + BCL-XL inhibitors|MEK inhibitor + IGF1R inhibitors|MEK inhibitor + PI3K pathway inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + BH3 mimeticss|pan-RAF inhibitors|pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitor + MEK inhibitors|Abemaciclib (CDK4/6 inhibitor)|Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)|Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)|Selumetinib (MEK inhibitor)|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor);Tumor_type=Pancreas|Lung|Non-small cell lung|Stomach|Any cancer type|Endometrium|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Colorectal adenocarcinoma|Lung|Lung|Lung|Cervix squamous cell|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung|Lung|Lung|Lung|Lung|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Colorectal adenocarcinoma|Lung;Billiary tract|Acute myeloid leukemia;Cervix;Ovary|Colorectal adenocarcinoma|Lung|Endometrium|Endometrium|Lung|Lung|Ovary|Pancreas|Non-small cell lung|Hepatic carcinoma|Lung adenocarcinoma
chr15	66727367	66727367	C	T	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727394	66727394	T	C	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727424	66727424	G	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727430	66727430	G	T	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727441	66727441	T	C	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727442	66727442	T	C	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727442	66727442	T	G	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727455	66727455	G	T	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727462	66727462	G	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727463	66727463	T	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66727483	66727483	G	A	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66729088	66729088	T	C	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66729100	66729100	T	A	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N)|MAP2K1 (F129L_L215P_I103N_P124);Evidence_level=Case report|Pre-clinical|Pre-clinical;Association=Resistant|Resistant|Responsive;Drug=EGFR mAb inhibitors|MEK inhibitors|ERK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type|Any cancer type
chr15	66729123	66729124	AT	CC	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729123	66729124	AT	GC	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729124	66729124	T	A	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66729124	66729124	T	G	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729124	66729125	TC	GG	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729136	66729136	T	C	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729148	66729148	A	C	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66729152	66729152	G	C	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66729152	66729152	G	T	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729154	66729154	G	C	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729159	66729159	T	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729163	66729163	C	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729175	66729175	G	A	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66729175	66729175	G	T	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729177	66729177	T	C	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (F129L_L215P_I103N_P124)|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Resistant;Drug=EGFR mAb inhibitors|ERK inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type|Any cancer type
chr15	66729181	66729181	A	G	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66729222	66729222	G	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66774135	66774135	T	C	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66774156	66774156	T	A	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Case report|Pre-clinical;Association=Resistant|Resistant;Drug=EGFR mAb inhibitors|MEK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type
chr15	66774168	66774168	T	C	Biomarker=MAP2K1 oncogenic mutation|MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N)|MAP2K1 (F129L_L215P_I103N_P124);Evidence_level=Case report|Pre-clinical|Pre-clinical;Association=Resistant|Resistant|Responsive;Drug=EGFR mAb inhibitors|MEK inhibitors|ERK inhibitors;Tumor_type=Colorectal adenocarcinoma|Any cancer type|Any cancer type
chr15	66774176	66774177	TC	GA	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66774188	66774189	TC	GA	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66777424	66777424	C	T	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr15	66779587	66779587	C	A	Biomarker=MAP2K1 oncogenic mutation;Evidence_level=Case report;Association=Resistant;Drug=EGFR mAb inhibitors;Tumor_type=Colorectal adenocarcinoma
chr17	29422382	29422382	G	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29496928	29496931	TGTT	-	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29508478	29508478	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29508778	29508778	C	G	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29527461	29527461	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29541542	29541542	A	G	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29546036	29546037	AG	-	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29550496	29550499	ACTA	-	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29552152	29552152	G	A	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29553483	29553483	-	C	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29553629	29553629	G	-	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29554272	29554272	T	C	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29556222	29556222	T	G	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29556253	29556253	-	A	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29559101	29559101	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29559860	29559863	CTCA	-	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29560133	29560133	C	G	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29560133	29560133	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29562641	29562641	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29562740	29562740	-	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29562747	29562747	G	A	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29562747	29562747	G	C	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29562967	29562967	T	G	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29562967	29562967	-	TATTACGAATTGT	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29563036	29563036	C	A	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29576094	29576094	A	G	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29652906	29652906	-	ATA	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29654857	29654857	G	A	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29657486	29657486	G	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29661882	29661882	G	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29665757	29665757	C	A	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29677227	29677227	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29677271	29677271	T	-	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29684326	29684326	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr17	29685622	29685622	C	T	Biomarker=NF1 oncogenic mutation;Evidence_level=Pre-clinical|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Case report|Case report|Late trials|Case report|Early trials|Pre-clinical|Pre-clinical|Early trials|Early trials|Case report|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early trials|Case report|Early trials|Case report;Association=Resistant|No Responsive|Resistant|Resistant|No Responsive|No Responsive|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|No Responsive|No Responsive;Drug=Retinoic Acids|Cediranib (ALK inhibitor)|Dasatinib (BCR-ABL inhibitor 2nd gen)|Erlotinib (EGFR inhibitor 1st gen)|Everolimus (MTOR inhibitor)|Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)|Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|AURK inhibitors|BRD4 inhibitors|KIT inhibitor + MTOR inhibitors|MEK inhibitors|MEK inhibitors|MTOR inhibitor + HSP90 inhibitors|MTOR inhibitors|Pan-RAF inhibitor + MEK inhibitors|PD1 Ab inhibitors|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Nilotinib (BCR-ABL inhibitor 2nd gen)|PLX3397 (Pan-TK inhibitor)|Selumetinib (MEK inhibitor)|Sirolimus (MTOR inhibitor)|Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)|Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)|Tamoxifen (Hormonal therapy)|Trametinib (MEK inhibitor)|Trametinib (MEK inhibitor)|Vinblastine (Chemotherapy)|Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)|Tipifarnib (Farnesyltransferase inhibitor)|Trametinib (MEK inhibitor);Tumor_type=Neuroblastoma|Plexiform neurofibroma|Lung|Lung|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma;Leukemia|Malignant peripheral nerve sheat tumor|Glioma;Malignant peripheral nerve sheat tumor;Leukemia|Cutaneous melanoma|Cutaneous melanoma|Glioma|Head an neck;Salivary glands|Neurofibroma|Hepatic carcinoma|Plexiform neurofibroma|Plexiform neurofibroma;Malignant peripheral nerve sheat tumor|Plexiform neurofibroma|Plexiform neurofibroma|Plexiform neurofibroma|Glioma|Malignant peripheral nerve sheat tumor|Malignant peripheral nerve sheat tumor|Glioma|Cutaneous melanoma|Glioma|Glioma|Plexiform neurofibroma|Osteosarcoma
chr22	30032762	30032762	T	G	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30032794	30032794	C	T	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30032816	30032816	T	C	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30032860	30032860	A	G	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30035155	30035155	A	G	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30054210	30054210	C	A	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30077457	30077457	T	C	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr22	30077466	30077466	A	C	Biomarker=NF2 oncogenic mutation;Evidence_level=Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Early trials|Early trials|Pre-clinical|Pre-clinical|Early trials|Case report;Association=No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=Erlotinib (EGFR inhibitor 1st gen)|FAK inhibitors|FAK inhibitors|HSP90 inhibitors|MEK inhibitors|MTOR inhibitors|PAK inhibitors|PDK1 inhibitors|AR42 (HDAC inhibitor)|AR42 (HDAC inhibitor)|Bevacizumab (VEGFR mAb inhibitor)|Everolimus (MTOR inhibitor)|Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)|Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)|Lapatinib (ERBB2 inhibitor)|Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy);Tumor_type=Schwannoma|Mesothelioma|Mesothelioma;Ovary|Meningioma|Thyroid|Meningioma|Schwannoma;Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma|Meningioma|Schwannoma|Schwannoma;Neurofibroma|Breast adenocarcinoma
chr9	139390902	139390902	C	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390906	139390906	G	C	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390907	139390907	G	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390918	139390918	C	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390933	139390933	C	A	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390942	139390942	G	C	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390945	139390945	G	A	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139390957	139390957	G	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139397648	139397648	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139397700	139397700	C	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139397762	139397762	A	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139397768	139397768	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139397774	139397774	A	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399132	139399132	C	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399296	139399296	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399296	139399296	A	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399344	139399344	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399350	139399350	C	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399356	139399356	A	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399362	139399362	C	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399365	139399365	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399368	139399368	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399416	139399416	A	T	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr9	139399422	139399422	A	G	Biomarker=NOTCH1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Gamma secretase inhibitors;Tumor_type=Mantle cell lymphoma
chr5	170837543	170837543	-	TCTG	Biomarker=NPM1 oncogenic mutation;Evidence_level=Pre-clinical|FDA guidelines;Association=Responsive|Responsive;Drug=DOT1L inhibitors + MLL1 inhibitors|Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia
chr5	170837545	170837545	-	CATG	Biomarker=NPM1 oncogenic mutation;Evidence_level=Pre-clinical|FDA guidelines;Association=Responsive|Responsive;Drug=DOT1L inhibitors + MLL1 inhibitors|Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia
chr5	170837545	170837545	-	CCTG	Biomarker=NPM1 oncogenic mutation;Evidence_level=Pre-clinical|FDA guidelines;Association=Responsive|Responsive;Drug=DOT1L inhibitors + MLL1 inhibitors|Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia
chr5	170837546	170837546	-	CAGT	Biomarker=NPM1 oncogenic mutation;Evidence_level=Pre-clinical|FDA guidelines;Association=Responsive|Responsive;Drug=DOT1L inhibitors + MLL1 inhibitors|Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia
chr5	170837546	170837546	-	CTGT	Biomarker=NPM1 oncogenic mutation;Evidence_level=Pre-clinical|FDA guidelines;Association=Responsive|Responsive;Drug=DOT1L inhibitors + MLL1 inhibitors|Daunorubicin (Chemotherapy);Tumor_type=Acute myeloid leukemia|Acute myeloid leukemia
chr1	115256528	115256528	T	G	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256528	115256528	T	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256528	115256529	TT	CA	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256529	115256529	T	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256528	115256529	TT	CC	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256529	115256529	T	C	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256529	115256530	TG	CT	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256529	115256529	T	G	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256530	115256530	G	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256530	115256530	G	C	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256530	115256530	G	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256532	115256532	C	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256538	115256538	G	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115256562	115256562	G	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258730	115258730	C	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258744	115258744	C	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258744	115258744	C	G	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258744	115258744	C	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258745	115258745	C	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258745	115258745	C	G	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258745	115258745	C	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258747	115258747	C	A	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258747	115258747	C	G	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258747	115258747	C	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258748	115258748	C	G	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr1	115258748	115258748	C	T	Biomarker=NRAS oncogenic mutation;Evidence_level=Early trials|Case report|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Pre-clinical|Early Trials_Case Report|Pre-clinical;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Resistant;Drug=CDK4/6 inhibitor + MEK inhibitors|ERK inhibitors|HSP90 inhibitors|MEK inhibitor +/- PI3K pathway inhibitors|MEK inhibitors|Pan-RAF inhibitors|PI3K pathway inhibitor + MEK inhibitors|Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)|Vemurafenib (BRAF inhibitor);Tumor_type=Cutaneous melanoma|Cutaneous melanoma|Cutaneous melanoma|Colorectal adenocarcinoma|Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia|Cutaneous melanoma|Myeloma|Hepatic carcinoma|Cutaneous melanoma
chr16	23614792	23614792	G	C	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614792	23614792	G	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614865	23614865	C	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614884	23614884	-	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614913	23614913	A	G	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614914	23614914	-	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614916	23614919	AAGT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23614980	23614980	C	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23619212	23619212	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23619270	23619271	CA	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23619279	23619279	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23619334	23619334	C	G	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23625324	23625324	C	G	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23625411	23625411	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23632683	23632683	C	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23632707	23632707	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23632751	23632751	A	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23632774	23632774	G	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23632792	23632795	CTTT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23634300	23634300	C	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23634323	23634323	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23634324	23634324	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23634354	23634354	-	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23634364	23634367	CTTT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23634366	23634367	TT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23635329	23635329	C	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23635348	23635348	A	C	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23637553	23637558	TTACCT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23637578	23637579	AA	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23637593	23637593	C	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23637658	23637658	-	CAAC	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23637709	23637709	C	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23640576	23640587	AGGAAGCTCTGC	TCTGA	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641004	23641004	-	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641081	23641087	AGGTTGT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641089	23641089	C	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641139	23641139	G	C	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641152	23641152	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641218	23641218	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641246	23641246	A	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641270	23641270	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641307	23641308	AT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641322	23641322	C	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641356	23641356	G	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641425	23641425	G	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641443	23641443	G	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641469	23641469	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641508	23641508	-	AAAAATACAGCTTCCTCTG	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641545	23641545	C	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641555	23641555	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23641751	23641751	C	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646191	23646192	TG	CA	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646223	23646224	TG	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646234	23646234	C	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646249	23646249	-	AA	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646278	23646278	A	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646325	23646325	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646390	23646390	G	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646416	23646416	A	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646552	23646552	C	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646577	23646578	CT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646609	23646609	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646627	23646627	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646781	23646782	AA	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646810	23646810	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646813	23646814	CT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646816	23646819	TTTG	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646828	23646832	CTTTT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646921	23646921	G	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23646927	23646927	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647016	23647016	-	T	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647082	23647082	A	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647108	23647108	-	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647111	23647112	AG	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647179	23647179	C	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647205	23647206	AC	TA	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647214	23647214	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647271	23647271	A	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647358	23647359	CT	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647443	23647443	T	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647644	23647644	T	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23647657	23647657	T	C	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23649186	23649186	G	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23649211	23649214	ACAA	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23649275	23649275	T	C	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23649395	23649395	A	G	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23649416	23649416	T	C	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23649427	23649427	C	-	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23652436	23652436	C	A	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr16	23652453	23652453	A	CG	Biomarker=PALB2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Case report|Case report;Association=Responsive|Responsive|Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors|Mytomycin C (Chemotherapy)|Platinum Agent (Chemotherapy);Tumor_type=Prostate adenocarcinoma|Pancreas|Pancreas|Pancreas
chr3	178916726	178916726	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916854	178916854	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916876	178916876	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916890	178916890	C	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916891	178916891	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916929	178916929	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916930	178916930	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916930	178916930	G	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916936	178916936	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916941	178916941	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916944	178916944	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178916946	178916946	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178917478	178917478	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178917496	178917496	C	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178917531	178917531	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178921549	178921549	T	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178921552	178921552	A	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178921553	178921553	T	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178921553	178921553	T	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178921567	178921567	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178922324	178922324	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178922363	178922363	T	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178927980	178927980	T	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178928067	178928067	C	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178928079	178928079	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178928079	178928079	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178928080	178928080	A	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936074	178936074	C	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936082	178936082	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936082	178936082	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936083	178936083	A	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936091	178936091	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936091	178936091	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936092	178936092	A	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936092	178936092	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936092	178936092	A	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936093	178936093	G	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936093	178936093	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936094	178936094	C	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936094	178936094	C	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936095	178936095	A	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936095	178936095	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936095	178936095	A	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178936103	178936103	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178937054	178937054	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178937753	178937753	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178947865	178947865	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178951994	178951994	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952007	178952007	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952018	178952018	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952019	178952019	C	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952018	178952018	A	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952030	178952030	G	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952072	178952072	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952074	178952074	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952074	178952074	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952074	178952074	G	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952077	178952077	T	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952084	178952084	C	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952085	178952085	A	G	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952085	178952085	A	T	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952090	178952090	G	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952090	178952090	G	C	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	178952147	178952147	-	A	Biomarker=PIK3CA oncogenic mutation;Evidence_level=Early trials|Late trials|Early trials|Pre-clinical|Case report|Early trials|Case report|Pre-clinical|Early trials|Case report;Association=No Responsive|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=PI3K pathway inhibitors|Cetuximab (EGFR mAb inhibitor)|AKT inhibitors|PI3K pathway inhibitor (alone or in combination)s|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PI3K pathway inhibitors|PIK3CA inhibitors|PIK3CA inhibitors;Tumor_type=Lung|Colorectal adenocarcinoma|Breast adenocarcinoma|Lung;Colorectal adenocarcinoma|Bladder;Head an neck;Lung|Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium|Head an neck squamous|Glioma;Thyroid carcinoma|Breast adenocarcinoma|Stomach
chr3	138374244	138374244	T	A	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr3	138374244	138374244	T	G	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr3	138374293	138374293	C	T	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr3	138409981	138409981	C	T	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr3	138417861	138417861	T	C	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr3	138417865	138417865	C	T	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr3	138478044	138478044	G	A	Biomarker=PIK3CB oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical;Association=Responsive|Responsive|Responsive;Drug=AKT inhibitors|MTORC1/2 inhibitors|PI3K pathway inhibitors;Tumor_type=Head an neck squamous|Head an neck squamous|Head an neck squamous
chr5	67569292	67569292	G	A	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67569817	67569817	G	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67569823	67569823	C	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67576373	67576373	G	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67576506	67576506	G	C	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67576780	67576780	A	C	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67588951	67588951	C	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67589138	67589138	G	A	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67589138	67589138	G	C	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67589147	67589147	A	G	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67589554	67589556	AGA	-	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67589618	67589618	C	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67590445	67590445	C	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591085	67591085	G	T	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591085	67591102	GACAAACGTATGAACAGC	-	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591097	67591097	A	G	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591099	67591099	C	A	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591099	67591099	C	G	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591134	67591136	CGA	-	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr5	67591250	67591252	GGT	-	Biomarker=PIK3R1 oncogenic mutation;Evidence_level=Pre-clinical|Case report;Association=Responsive|Responsive;Drug=AKT inhibitors|PI3K pathway inhibitors;Tumor_type=Glioma|Endometrium
chr12	133249847	133249847	G	A	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133250250	133250250	G	C	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133250250	133250250	G	T	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133250289	133250289	C	G	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133252327	133252327	A	G	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133253151	133253151	G	A	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133253184	133253184	G	C	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133253184	133253184	G	T	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr12	133253185	133253185	G	A	Biomarker=POLE oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=PD1 Ab inhibitors;Tumor_type=Colorectal adenocarcinoma
chr9	98215869	98215869	T	A	Biomarker=PTCH1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|FDA guidelines;Association=Responsive|Responsive|Responsive;Drug=SMO inhibitors|Foretinib (MET inhibitor)|Vismodegib (SHH inhibitor);Tumor_type=Medulloblastoma|Medulloblastoma|Basal cell carcinoma;Medulloblastoma
chr10	89624247	89624248	GA	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624255	89624255	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624268	89624268	G	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624270	89624270	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624271	89624271	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624271	89624271	-	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624273	89624273	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624274	89624274	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624275	89624275	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624276	89624277	AA	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624281	89624281	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624285	89624285	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624287	89624288	TT	GC	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624295	89624295	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624296	89624296	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624296	89624296	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624296	89624296	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89624305	89624305	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653781	89653781	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653782	89653782	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653782	89653782	-	CT	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653787	89653790	TATC	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653803	89653803	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653806	89653806	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653807	89653808	GG	AC	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653808	89653808	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653808	89653808	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653815	89653815	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653817	89653817	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653819	89653819	A	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653827	89653827	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653833	89653833	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653832	89653832	-	GCGT	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653841	89653841	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89653846	89653846	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685269	89685269	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685286	89685286	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685287	89685287	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685290	89685290	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685299	89685299	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685307	89685307	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685307	89685307	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89685314	89685314	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89690805	89690805	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89690811	89690811	-	AAGA	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89690828	89690828	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89690847	89690847	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692768	89692768	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692790	89692790	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692790	89692790	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692791	89692791	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692791	89692791	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692791	89692791	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692792	89692792	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692793	89692793	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692793	89692793	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692794	89692794	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692795	89692795	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692797	89692797	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692799	89692799	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692800	89692800	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692802	89692802	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692803	89692803	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692805	89692805	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692817	89692817	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692830	89692830	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692835	89692835	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692836	89692836	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692837	89692837	T	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692839	89692839	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692851	89692851	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692851	89692851	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692869	89692869	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692877	89692877	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692878	89692878	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692878	89692878	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692880	89692880	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692881	89692881	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692883	89692883	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692883	89692883	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692885	89692885	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692886	89692886	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692886	89692886	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692886	89692887	TG	AA	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692889	89692889	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692889	89692890	AA	CT	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692890	89692891	AA	TG	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692892	89692892	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692893	89692893	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692893	89692893	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692893	89692893	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692895	89692897	GGA	AAC	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692896	89692896	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692898	89692898	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692899	89692899	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692899	89692899	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692900	89692900	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692901	89692901	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692902	89692902	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692902	89692902	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692902	89692903	GA	AC	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692904	89692904	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692904	89692904	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692904	89692905	CG	AA	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692904	89692905	CG	GC	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692905	89692905	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692905	89692905	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692905	89692905	G	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692907	89692907	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692907	89692907	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692907	89692908	AC	CT	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692908	89692908	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692913	89692913	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692916	89692916	A	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692919	89692919	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692920	89692920	-	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692922	89692922	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692923	89692923	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692953	89692953	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692953	89692953	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692964	89692964	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692976	89692976	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692979	89692979	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692980	89692980	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692986	89692986	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692991	89692991	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692993	89692993	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692995	89692995	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89692997	89692997	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89693000	89693000	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89693001	89693001	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89693007	89693007	A	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711873	89711873	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711874	89711874	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711875	89711875	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711875	89711875	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711876	89711876	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711876	89711876	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711881	89711881	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711884	89711884	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711888	89711888	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711891	89711891	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711892	89711892	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711893	89711893	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711894	89711894	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711899	89711899	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711900	89711900	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711900	89711900	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711902	89711902	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711909	89711909	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711922	89711922	C	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711924	89711924	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711929	89711931	AAG	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711946	89711946	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89711967	89711967	T	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89712015	89712015	C	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717624	89717624	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717625	89717625	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717655	89717655	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717672	89717672	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717675	89717675	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717680	89717680	-	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717697	89717697	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717708	89717708	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717712	89717712	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717713	89717713	-	AT	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717715	89717715	-	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717726	89717726	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717730	89717730	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717733	89717736	TCAA	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717746	89717747	CT	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717747	89717748	TT	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717775	89717775	A	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89717777	89717777	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720649	89720649	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720649	89720649	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720670	89720670	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720671	89720671	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720676	89720676	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720699	89720699	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720714	89720714	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720723	89720723	-	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720733	89720733	-	TT	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720741	89720741	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720741	89720741	C	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720768	89720768	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720772	89720772	-	TGCAG	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720804	89720804	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720803	89720803	-	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720813	89720813	A	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720822	89720822	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720825	89720825	G	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720836	89720839	TAAA	-	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720841	89720841	A	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720852	89720852	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720853	89720853	G	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720870	89720870	T	G	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720875	89720875	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89720876	89720876	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89725044	89725044	G	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89725045	89725045	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89725051	89725051	T	A	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89725056	89725056	T	C	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr10	89725219	89725219	C	T	Biomarker=PTEN oncogenic mutation;Evidence_level=Late trials|Early trials|Case report|Pre-clinical|Case report|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Case report|Early trials|Early trials;Association=Resistant|No Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=EGFR mAb inhibitors|MTOR inhibitors|AKT inhibitors|ATM inhibitors|PARP inhibitors|PD1 Ab inhibitors|PI3K pathway inhibitor + AR antagonists|PI3K pathway inhibitor + MEK inhibitors|PI3K pathway inhibitors|PIK3CB inhibitors|Everolimus (MTOR inhibitor)|Sirolimus (MTOR inhibitor);Tumor_type=Colorectal adenocarcinoma|Endometrium|Pancreas|Breast adenocarcinoma|Endometrium|Cutaneous melanoma|Prostate adenocarcinoma|Ovary|Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium|Prostate adenocarcinoma|Prostate adenocarcinoma|Any cancer type
chr9	8341947	8341947	C	T	Biomarker=PTPRD oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=IGF1R inhibitors;Tumor_type=Sarcoma
chr9	8449782	8449782	G	T	Biomarker=PTPRD oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=IGF1R inhibitors;Tumor_type=Sarcoma
chr9	8484270	8484270	G	A	Biomarker=PTPRD oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=IGF1R inhibitors;Tumor_type=Sarcoma
chr9	8518054	8518054	C	T	Biomarker=PTPRD oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=IGF1R inhibitors;Tumor_type=Sarcoma
chr17	56770097	56770097	G	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56770101	56770101	C	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772304	56772304	C	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772327	56772328	CT	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772332	56772333	AA	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772362	56772366	ACCAA	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772369	56772369	-	A	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772539	56772539	-	A	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56772552	56772552	T	C	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56774063	56774063	G	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56774124	56774124	G	A	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56774149	56774149	-	TA	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56774151	56774151	A	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56780562	56780562	C	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56780562	56780564	CGA	TGG	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56780563	56780563	G	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56780615	56780615	T	G	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56780638	56780639	AG	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56780686	56780686	C	G	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56787218	56787218	A	G	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56787223	56787223	C	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56787287	56787287	G	A	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56801398	56801402	CAGGG	-	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56801451	56801451	C	T	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr17	56801462	56801462	G	A	Biomarker=RAD51C oncogenic mutation;Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=PARP inhibitors|PARP inhibitors;Tumor_type=Ovary|Ovary
chr13	48878151	48878151	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48881504	48881504	-	TA	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48919244	48919244	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48919281	48919281	C	G	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48919297	48919297	-	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48921968	48921968	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48923148	48923148	T	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48936995	48936995	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48939051	48939051	-	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48939105	48939105	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48941648	48941648	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48941740	48941740	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48941740	48941740	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48942685	48942685	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48947559	48947559	-	C	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48947579	48947579	T	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48947629	48947629	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48951053	48951053	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48951171	48951171	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48951171	48951171	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48953743	48953743	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48953760	48953760	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48954198	48954198	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48955538	48955538	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48955550	48955550	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48955572	48955572	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	48955580	48955580	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49027133	49027133	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49027156	49027156	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49027168	49027168	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49027171	49027171	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030344	49030344	C	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030386	49030386	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030434	49030434	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030450	49030450	T	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030452	49030452	A	G	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030485	49030485	G	C	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49030487	49030487	T	C	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49033822	49033822	A	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49033836	49033836	C	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49033844	49033844	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49033955	49033955	A	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49033964	49033964	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49037866	49037866	G	C	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49037877	49037877	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49037924	49037924	A	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49037957	49037957	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49037969	49037969	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49039133	49039133	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49039149	49039149	-	TGAT	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49039164	49039164	G	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49039169	49039169	T	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49039374	49039374	C	T	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49047495	49047495	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49047527	49047527	G	A	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49050840	49050840	-	C	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr13	49050981	49050981	T	C	Biomarker=RB1 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Early trials;Association=Responsive|Responsive|Responsive;Drug=HDAC inhibitors|MDM2/MDMX inhibitors|Cisplatin (Chemotherapy);Tumor_type=Retinoblastoma|Retinoblastoma|Bladder
chr3	47144880	47144880	G	A	Biomarker=SETD2 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=WEE1 inhibitors;Tumor_type=Any cancer type
chr19	11132513	11132513	C	T	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11134256	11134256	C	-	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11134266	11134266	C	T	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11138521	11138521	C	T	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11141502	11141502	-	G	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11143984	11143984	C	T	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11144114	11144114	G	A	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr19	11170460	11170460	T	-	Biomarker=SMARCA4 oncogenic mutation;Evidence_level=Case report;Association=Responsive;Drug=EZH2 inhibitors;Tumor_type=Ovary
chr17	74732959	74732959	G	T	Biomarker=SRSF2 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=Spliceosome inhibitors;Tumor_type=Acute myeloid leukemia
chr19	1207020	1207020	C	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207021	1207021	C	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207046	1207057	TCATCGGCAAGT	-	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207057	1207057	T	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207080	1207080	-	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207112	1207112	T	C	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207130	1207142	GCAGGAGGGCCGT	-	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207144	1207145	AA	GC	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207145	1207146	AG	TC	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1207162	1207162	A	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1219344	1219344	C	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1219350	1219351	TG	-	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1219351	1219351	G	C	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1219355	1219355	T	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1219357	1219357	C	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1219413	1219413	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220394	1220394	G	C	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220395	1220395	G	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220415	1220415	C	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220428	1220428	A	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220433	1220433	G	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220437	1220437	T	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220450	1220450	C	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220452	1220452	T	C	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220481	1220481	A	-	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220487	1220487	G	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220487	1220487	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220488	1220488	A	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220489	1220489	C	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220494	1220494	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220502	1220502	G	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220502	1220502	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220595	1220595	G	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220698	1220698	G	C	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220701	1220701	C	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1220717	1220717	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221319	1221319	C	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221319	1221319	C	-	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221320	1221320	-	C	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221341	1221341	T	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221962	1221962	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221974	1221974	A	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221976	1221976	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221984	1221984	T	-	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1221995	1221995	C	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1222982	1222982	A	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1222983	1222983	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1222987	1222987	G	T	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1223050	1223050	-	G	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr19	1223059	1223059	G	A	Biomarker=STK11 oncogenic mutation;Evidence_level=Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical|Pre-clinical;Association=Resistant|Responsive|Responsive|Responsive|Responsive;Drug=BET inhibitors|MEK inhibitors|MTOR inhibitors|SRC inhibitor + PI3K/MEK inhibitors|Phenformin (Anti-diabetic);Tumor_type=Lung|Lung adenocarcinoma|Any cancer type|Lung adenocarcinoma|Lung adenocarcinoma
chr17	7572984	7572984	C	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573931	7573931	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573934	7573934	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573951	7573951	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573983	7573983	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573984	7573984	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573987	7573987	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573988	7573988	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573996	7573996	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7573996	7573996	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574002	7574002	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574003	7574003	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574005	7574005	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574015	7574015	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574017	7574017	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574017	7574017	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574017	7574017	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574018	7574018	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574030	7574030	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574034	7574034	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7574034	7574034	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576853	7576853	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576854	7576854	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576857	7576857	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576857	7576857	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576857	7576857	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576864	7576864	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576869	7576870	TC	AG	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576872	7576872	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576873	7576873	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576899	7576899	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576921	7576921	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7576927	7576927	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577022	7577022	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577024	7577024	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577034	7577034	C	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577046	7577046	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577058	7577058	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577063	7577063	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577063	7577063	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577067	7577067	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577067	7577067	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577069	7577069	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577069	7577069	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577070	7577070	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577079	7577079	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577081	7577081	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577082	7577082	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577084	7577084	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577085	7577085	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577089	7577090	GC	TT	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577089	7577089	-	CGCC	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577091	7577091	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577093	7577093	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577094	7577094	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577094	7577094	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577094	7577101	GGTCTCTC	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577096	7577096	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577096	7577096	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577099	7577099	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577099	7577099	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577099	7577100	CT	GC	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577105	7577105	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577105	7577105	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577106	7577106	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577106	7577106	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577107	7577107	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577107	7577109	ACA	TTG	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577109	7577109	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577114	7577114	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577114	7577114	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577115	7577115	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577118	7577118	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577119	7577121	ACG	CTT	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577120	7577120	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577120	7577120	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577121	7577121	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577121	7577121	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577121	7577121	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577123	7577123	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577123	7577132	ACCTCAAAGC	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577124	7577124	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577124	7577124	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577124	7577124	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577138	7577138	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577138	7577138	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577141	7577141	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577142	7577142	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577144	7577144	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577148	7577150	GAT	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577156	7577156	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577508	7577508	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577509	7577509	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577511	7577511	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577511	7577511	A	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577518	7577518	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577520	7577520	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577528	7577528	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577528	7577528	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577529	7577529	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577530	7577530	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577532	7577532	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577534	7577534	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577534	7577534	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577535	7577535	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577535	7577535	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577536	7577536	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577538	7577538	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577538	7577539	CG	TT	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577539	7577539	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577544	7577544	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577545	7577545	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577547	7577547	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577547	7577547	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577548	7577548	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577548	7577548	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577550	7577550	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577551	7577551	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577551	7577551	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577552	7577552	C	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577556	7577556	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577556	7577556	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577557	7577557	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577559	7577559	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577559	7577559	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577560	7577560	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577561	7577561	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577561	7577561	A	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577565	7577565	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577568	7577568	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577568	7577568	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577569	7577569	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577569	7577569	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577570	7577570	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577571	7577571	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577572	7577572	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577574	7577574	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577574	7577574	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577575	7577575	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577575	7577577	AGT	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577577	7577577	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577578	7577578	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577580	7577580	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577581	7577581	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577584	7577584	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577584	7577584	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577591	7577598	GGTACAGT	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577595	7577596	CA	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577596	7577596	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577602	7577602	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577609	7577609	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7577610	7577610	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578176	7578176	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578176	7578176	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578184	7578184	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578190	7578190	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578190	7578190	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578194	7578194	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578204	7578204	A	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578206	7578206	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578206	7578206	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578206	7578206	T	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578207	7578207	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578207	7578224	ATGTCGAAAAGTGTTTCT	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578208	7578208	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578209	7578209	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578211	7578211	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578211	7578211	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578212	7578212	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578216	7578216	A	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578221	7578221	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578224	7578224	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578225	7578226	GT	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578234	7578234	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578235	7578235	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578245	7578245	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578253	7578253	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578254	7578254	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578259	7578259	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578260	7578260	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578260	7578260	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578262	7578262	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578263	7578263	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578265	7578265	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578269	7578269	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578271	7578271	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578271	7578271	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578272	7578272	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578272	7578272	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578279	7578280	AG	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578280	7578280	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578290	7578290	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578291	7578291	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578369	7578369	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578370	7578370	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578373	7578373	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578380	7578380	C	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578388	7578388	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578388	7578388	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578388	7578388	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578389	7578389	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578392	7578392	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578393	7578393	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578394	7578394	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578394	7578394	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578395	7578395	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578395	7578395	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578398	7578398	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578400	7578400	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578402	7578402	G	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578403	7578403	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578404	7578404	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578406	7578406	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578407	7578407	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578407	7578407	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578410	7578410	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578412	7578412	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578412	7578412	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578412	7578412	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578413	7578413	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578413	7578413	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578414	7578414	-	ACCTC	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578416	7578416	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578421	7578424	GTCA	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578427	7578427	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578428	7578428	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578428	7578428	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578437	7578437	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578442	7578442	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578443	7578443	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578444	7578444	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578449	7578449	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578449	7578449	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578457	7578457	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578457	7578457	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578458	7578458	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578458	7578458	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578460	7578460	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578461	7578461	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578461	7578461	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578463	7578463	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578464	7578464	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578466	7578466	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578472	7578472	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578472	7578484	GGCGGGGGTGTGG	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578475	7578475	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578478	7578478	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578479	7578479	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578479	7578479	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578479	7578479	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578478	7578478	-	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578480	7578480	T	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578481	7578481	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578482	7578494	TGGAATCAACCCA	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578493	7578493	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578496	7578496	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578499	7578499	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578499	7578499	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578499	7578499	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578502	7578502	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578508	7578508	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578517	7578517	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578518	7578518	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578518	7578518	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578524	7578524	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578526	7578526	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578527	7578527	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578527	7578527	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578529	7578529	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578532	7578532	A	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578532	7578532	A	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578532	7578532	A	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578536	7578536	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578536	7578536	T	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578538	7578538	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578539	7578539	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578542	7578542	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7578553	7578553	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579311	7579311	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579312	7579312	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579312	7579312	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579323	7579324	CA	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579325	7579325	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579327	7579327	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579328	7579328	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579328	7579328	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579328	7579329	TT	GC	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579329	7579329	T	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579329	7579329	T	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579349	7579351	AAG	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579358	7579358	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579358	7579358	C	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579358	7579358	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579360	7579360	G	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579369	7579369	G	C	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579374	7579374	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579378	7579378	G	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579389	7579389	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579392	7579395	AAGG	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579398	7579398	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579402	7579404	AGA	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579442	7579442	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579475	7579475	-	G	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579529	7579529	-	ATT	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579536	7579536	C	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579550	7579550	G	AC	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579575	7579575	G	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579582	7579582	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579591	7579591	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579705	7579705	C	T	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7579843	7579843	T	-	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr17	7590694	7590694	C	A	Biomarker=TP53 oncogenic mutation;Evidence_level=Early trials|Early trials|Early trials|Pre-clinical|Early trials|Early trials|Pre-clinical|Pre-clinical|Pre-clinical|Early trials|Pre-clinical;Association=Resistant|Resistant|Resistant|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MDM2 inhibitors|Abemaciclib (CDK4/CDK6 inhibitor)|Cisplatin (Chemotherapy)|WEE1 inhibitors|AZD6738 (ATR inhibitor)|Decitabine (Chemotherapy)|Doxorubicin (Anthracycline antitumor antibiotic)|Gemcitabine (Chemotherapy)|Mitomycin C (Chemotherapy)|WEE1 inhibitors|Pramlintide (Amylin analogue);Tumor_type=Liposarcoma|Breast adenocarcinoma|Female germ cell tumor;Male germ cell tumor|Head an neck|B cell lymphoma|Acute myeloid leukemia;Myelodisplasic proliferative syndrome|Bladder|Bladder|Bladder|Ovary|Thymic
chr9	135787771	135787772	AT	-	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135796816	135796816	A	C	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135797211	135797211	C	A	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135797222	135797223	AA	GC	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135797253	135797253	G	C	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135797297	135797297	A	T	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135797330	135797330	A	G	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135798770	135798770	A	C	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135800987	135800987	A	G	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135801023	135801023	T	C	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135802595	135802595	T	C	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr9	135804155	135804157	AGA	TTG	Biomarker=TSC1 oncogenic mutation;Evidence_level=Early trials|Early trials|Case report|FDA guidelines|Case report|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Bladder|Renal|Giant cell astrocytoma|Sarcoma;Stomach|Renal angiomyolipoma
chr16	2100486	2100486	A	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2104397	2104397	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2108795	2108795	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2110677	2110677	G	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2111981	2111981	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2112521	2112521	C	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2112583	2112583	T	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2112995	2112995	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2114306	2114306	C	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2114307	2114307	T	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2114343	2114343	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2120529	2120529	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2120533	2120533	A	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2120571	2120571	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2120572	2120572	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2121512	2121512	C	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2121515	2121515	T	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2121925	2121925	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2122257	2122257	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2122258	2122258	T	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2122935	2122935	T	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2124220	2124220	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2124322	2124322	T	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2124334	2124334	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2124376	2124376	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2126094	2126094	G	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2126142	2126142	C	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2126142	2126142	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2126143	2126143	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2129172	2129172	T	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2130366	2130366	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2130376	2130376	C	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2134716	2134716	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2134966	2134966	A	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2135323	2135323	G	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136231	2136231	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136242	2136242	T	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136282	2136282	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136318	2136318	G	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136359	2136359	T	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136742	2136742	A	G	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136751	2136751	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136840	2136840	T	C	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2136841	2136841	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2137891	2137891	G	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2137892	2137892	T	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2137898	2137898	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2138106	2138106	C	T	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr16	2138118	2138118	G	A	Biomarker=TSC2 oncogenic mutation;Evidence_level=Early trials|Pre-clinical|Early trials|FDA guidelines;Association=Responsive|Responsive|Responsive|Responsive;Drug=MTOR inhibitors|SRC inhibitors|Everolimus (MTOR inhibitor)|Everolimus (MTOR inhibitor);Tumor_type=Renal angiomyolipoma|Lymphangioleiomyomatosis|Bladder|Renal angiomyolipoma;Giant cell astrocytoma
chr21	44514777	44514777	T	C	Biomarker=U2AF1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=FLT3 inhibitors;Tumor_type=Any cancer type
chr21	44514777	44514777	T	G	Biomarker=U2AF1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=FLT3 inhibitors;Tumor_type=Any cancer type
chr21	44524456	44524456	G	A	Biomarker=U2AF1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=FLT3 inhibitors;Tumor_type=Any cancer type
chr21	44524456	44524456	G	T	Biomarker=U2AF1 oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=FLT3 inhibitors;Tumor_type=Any cancer type
chr3	10183685	10183685	G	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183711	10183711	G	-	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183719	10183719	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183722	10183722	G	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183723	10183723	C	-	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183724	10183724	T	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183725	10183725	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183725	10183725	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183734	10183734	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183736	10183736	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183739	10183739	G	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183750	10183751	GG	-	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183758	10183758	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183764	10183764	A	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183772	10183772	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183776	10183776	G	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183785	10183785	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183788	10183788	C	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183788	10183788	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183794	10183794	G	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183797	10183797	T	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183797	10183797	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183800	10183800	A	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183818	10183818	A	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183823	10183823	T	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183823	10183823	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183862	10183862	A	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183864	10183864	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183865	10183865	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183865	10183865	T	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183871	10183871	G	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10183872	10183872	G	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188201	10188201	A	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188202	10188202	C	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188208	10188208	G	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188210	10188210	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188210	10188210	T	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188213	10188213	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188219	10188219	A	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188302	10188302	G	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188302	10188302	G	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188307	10188307	T	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10188309	10188309	T	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191470	10191470	G	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191471	10191471	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191479	10191479	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191480	10191480	T	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191480	10191480	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191484	10191484	A	-	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191488	10191488	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191489	10191489	G	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191492	10191492	G	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191498	10191498	A	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191504	10191504	T	C	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191506	10191506	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191507	10191507	G	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191532	10191532	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191555	10191555	C	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191569	10191569	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191570	10191570	T	A	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191578	10191578	C	G	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191605	10191605	C	T	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr3	10191621	10191622	GC	-	Biomarker=VHL oncogenic mutation;Evidence_level=Pre-clinical;Association=Responsive;Drug=VEGFR inhibitors (Sorafenib_Sunitinib_Bevacizumab_Axitinib_etc);Tumor_type=Renal
chr7	55242487	55242489	CCG	CCTAGC	Biomarker=EGFR inframe deletion (L747)_inframe insertion (P753PS);Evidence_level=Case report;Association=No Responsive;Drug=Gefitinib (EGFR inhibitor 1st gen);Tumor_type=Head an neck
chr17	37880994	37880996	GCT	TATGTAATGGCA	Biomarker=ERBB2 inframe insertion (A775YVMA)_inframe insertion (G776VC)|ERBB2 inframe insertion (P780GSP)_inframe insertion (781GSP)_inframe insertion (A775YVMA)_inframe insertion (G776YVMA);Evidence_level=Early trials|Early trials;Association=Responsive|Responsive;Drug=Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)|Neratinib (ERBB2 inhibitor);Tumor_type=Lung|Any cancer type
chr17	37880997	37880999	GGT	GTATGT	Biomarker=ERBB2 inframe insertion (A775YVMA)_inframe insertion (G776VC);Evidence_level=Early trials;Association=Responsive;Drug=Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor);Tumor_type=Lung
chr17	37880997	37880999	GGT	TATGTAATGGCA	Biomarker=ERBB2 inframe insertion (P780GSP)_inframe insertion (781GSP)_inframe insertion (A775YVMA)_inframe insertion (G776YVMA);Evidence_level=Early trials;Association=Responsive;Drug=Neratinib (ERBB2 inhibitor);Tumor_type=Any cancer type
chr17	37881009	37881011	CCA	GGTAGCCCT	Biomarker=ERBB2 inframe insertion (P780GSP)_inframe insertion (781GSP)_inframe insertion (A775YVMA)_inframe insertion (G776YVMA);Evidence_level=Early trials;Association=Responsive;Drug=Neratinib (ERBB2 inhibitor);Tumor_type=Any cancer type
chr10	123256215	123256215	T	C	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123258039	123258039	T	C	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123258042	123258042	T	C	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123247516	123247516	T	C	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123256060	123256060	A	T	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123258076	123258076	C	G	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123258067	123258067	C	G	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr10	123258070	123258070	C	G	Biomarker=FGFR2 (M536I_M538I_I548V_N550_E566G_L618M_K660E)|FGFR2 (V565I_M536I_M538I_I548V_N550_E566G_L618M_K660E);Evidence_level=Pre-clinical|Pre-clinical;Association=Responsive|Resistant;Drug=Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)|Dovitinib (FGFR inhibitor);Tumor_type=Endometrium|Endometrium
chr4	55593609	55593609	G	A	Biomarker=KIT (V559I_H697Y_T670_V654A_A829P_D816_N822_Y823D);Evidence_level=Pre-clinical;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Gastrointestinal stromal
chr4	55599341	55599341	T	G	Biomarker=KIT (V559I_H697Y_T670_V654A_A829P_D816_N822_Y823D);Evidence_level=Pre-clinical;Association=Resistant;Drug=Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor);Tumor_type=Gastrointestinal stromal
chr15	66729189	66729189	T	C	Biomarker=MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Pre-clinical;Association=Resistant;Drug=MEK inhibitors;Tumor_type=Any cancer type
chr15	66729104	66729104	A	C	Biomarker=MAP2K1 (I99T_L115_G128D_F129L_V211D_L215P_I103N_K104N_I111N_H119P_E120D_F133L_P124_D67N);Evidence_level=Pre-clinical;Association=Resistant;Drug=MEK inhibitors;Tumor_type=Any cancer type
chr7	116423414	116423414	A	G	Biomarker=MET (Y1230C;Y1235D);Evidence_level=Pre-clinical;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Any cancer type
chr7	116423428	116423428	T	G	Biomarker=MET (Y1230C;Y1235D);Evidence_level=Pre-clinical;Association=Resistant;Drug=Crizotinib (ALK inhibitor);Tumor_type=Any cancer type
chr3	38182641	38182641	T	C	Biomarker=MYD88 (L265P);Evidence_level=FDA guidelines;Association=Responsive;Drug=Ibrutinib (BTK inhibitor);Tumor_type=Waldenström macroglobulinemia
